

# CURRICULUM VITAE

Morris Notelovitz, M.D., Ph.D.

M.B.B.Ch., F.R.C.O.G., F.A.C.O.G.

Consultant: Adult Women's Health & Medicine

Co-Founder: Adult Women's Health Alliance

Founder & Chief Scientific Officer: Cognifem LLC

4279 NW 61 Lane  
Boca Raton Fl 33496  
tel: 561.912.1323  
fax: 561.912.1323

e-mail: [mnotelo@aol.com](mailto:mnotelo@aol.com)

July 2010

## INDEX

<b>Brief Introduction</b> .....	2
<b>Executive summary</b> .....	3
<b>Personal Information</b> .....	4
<b>Education</b> .....	5
<b>Training</b> .....	5
<b>Professional Experience</b> .....	6
Academic	
Private Practice	
Consultant–Lecturer–Teacher	
Private Business	
<b>Professional Licensure and Board Certification</b> .....	7
General Practice	
Specialist Practice (Obstetrics and Gynecology)	
<b>Visiting Professor and Consultant</b> .....	8
<b>Professional Organization Memberships</b> .....	8
Past (RSA)	
Past and Present (USA)	
<b>Committees</b> .....	9
Past	
<b>Awards and Honors</b> .....	9
<b>Editorial Responsibilities</b> .....	10
Past	
<b>Medical Advisory Boards and Consultant</b> .....	11
<b>Publications</b>	
Thesis.....	12
Books.....	13
Book Chapters.....	14
Monographs.....	18
Abstracts.....	18
<b>Journal Articles</b>	
Hormone Therapy and Menopause.....	22
Osteoporosis.....	28
Exercise.....	29
Innovations in Medical Practice.....	31
Contraception.....	32
Preventive/Diagnostic/Evidence-based Medicine.....	33
Obstetrical Care.....	34
Gynecological/Surgical Practice.....	35
Original Clinical Observations.....	35
Hypothesis.....	35
Diabetes and Pregnancy.....	36
Basic Research/Animal Research/Physiology.....	38
Miscellaneous Writing.....	39
Articles translated into foreign languages.....	41
Audio-visual/education materials.....	41
Funded Research Support.....	42
Student and Graduate Research.....	47
Participation in International Meetings.....	48
Patents.....	54

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

BRIEF SUMMARY:

Dr Morris Notelovitz is a Board Certified gynecologist and Fellow of both the American and the Royal Collages of Obstetrics and Gynecology. He has served in senior academic positions and in private practice both in South Africa and in the United States.

In 1984 he introduced the concept of Climacteric medicine and science as a clinical and societal need, and later, chaired a series of global regional meetings resulting in the International Menopause Society's *Health Plan for the Adult Woman* handbook.

He is founder of the Adult Women's Health Alliance, a non profit multidisciplinary consortium of national healthcare organizations. Based on the clinical application of validated science the mission of the Alliance is the promotion of health and prevention of disease in adult women.

Dr Notelovitz has authored over 280 articles, chapters and abstracts on adult women's health issues, four books for the lay public and has co-edited five books for physicians. He is a Consultant in Adult Women's Health and Medicine, President of the Adult Women's Health Alliance and Chief Scientific Officer of Cognifem LLC, a company based on predictive medicine and preventive therapeutics.

Dr Notelovitz is based in Boca Raton, Florida.

**MORRIS NOTELOVITZ**  
*MD PhD MB BCh FRCOG FACOG*

CURRICULUM VITAE : EXECUTIVE SUMMARY

Morris Notelovitz M.D. Ph.D. is a graduate of the University of Witwatersrand, Johannesburg R.S.A., where he received his medical degree (MB, BCh) in 1958. This was followed by a Doctorate in Medicine (M.D) from his alma mater in 1968 and a Ph.D. in Medicine from the University of Stellenbosch (1977) for original research that defined insulin-independent diabetes in young pregnant Natal Indians. He was made a member of the Royal College of Obstetricians and Gynaecologists in 1964 and was elected as a Fellow of the College in 1978. He is also a Fellow of the American College of Obstetricians and Gynecologists (1978).

Dr Notelovitz has had a special interest in the menopause and midlife issues since 1969. Based on early experience gained in two traditional menopause clinics (Addington Hospital 1969; University of Florida 1976), Dr Notelovitz established the first multidisciplinary research center addressing gynecologic and non-gynecologic climacteric and menopausal issues, The Center for Climacteric Studies at the University of Florida (1980-1985). Research and clinical experience at this institute, resulted in the formation of a broader concept of adult women's health and medicine for the care of younger and peri / postmenopausal women. Practical outcomes included natural management principles (personalized nutrition and exercise prescription) and individualized hormone and other therapy decided on evidence-based biologic observations.

Dr Notelovitz is the Founder and President Emeritus of the Women's Medical and Diagnostic Center Inc., The Women's Research Center Inc., and Woman to Women America program, Gainesville FL (1986-1997). Based in one facility, this center offered comprehensive multidisciplinary integrated health-care for adult women as well as providing for their participation in clinical research and educational activities. The Women's Medical & Diagnostic Center Inc. has been featured on national and international TV programs as a model of integrated healthcare for adult women. This approach led to the recent formation of the Adult Women's Health Alliance (AWHA), a multi-disciplinary not-for-profit consortium of healthcare organizations with the unified goal of health promotion.

Dr Notelovitz has been the principal investigator in 76 clinical investigations and has been awarded two National Institute of Health grants. He has been involved in osteoporosis research and management since 1980. Other continuing research interests include: individualizing of hormonal and other therapies to enhance postmenopausal health based on genomic, biologic and applied pharmacologic/genomic principles; age adjusted nutrition and exercise for adult women, design of women's lifestyle facilities and the development of clinical protocols and paradigms for the practice of adult women's health and medicine with the objective of promoting predictive and preventive healthcare for women across their lifecycle.

Published work includes over 210 (mainly) peer reviewed articles, 31 abstracts and 42 chapters contributed to various medical texts. He is the principal author of four major books for the lay public: *Stand Tall! Every Woman's Guide to Preventing Osteoporosis*, *The Essential Heart Book for Women, Menopause & Midlife Health*, a comprehensive review of midlife health issues, and *Estrogen: Yes or No*. He was also the founder and publisher of the nation's first medical journal for consumers, the *Women's Health Digest*. He has edited five books for physicians, including the International Menopause Society's handbook *Health Plan for the Adult Woman*. He is the author of the physician handbook on osteoporosis, *Osteoporosis: Prevention, Diagnosis and Management* (now in the 4<sup>th</sup> edition).

Dr Notelovitz is currently a consultant in Adult Women's Health and Medicine; President of the AWHA and Chief Scientific Officer of Cognifem LLC a company formed to develop disease specific predictive and preventive strategies and products. He lectures and teaches nationally and internationally, having participated in 140 international workshops, advisory boards and conferences.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

**PERSONAL INFORMATION**

<u>Name</u>	Morris Notelovitz, M.D., Ph.D. M.B.B.Ch., F.R.C.O.G., F.A.C.O.G.
<u>Home Address</u>	4279 NW 61 Lane Boca Raton, FL 33496 561-912-1323 Fax: 561-912-1324
	e-mail: Mnotelo@aol.com
<u>Date/Place of Birth</u>	April 17, 1935/Pietersburg, R.S.A.
<u>Citizenship</u>	Naturalized U.S. citizen (02/07/84)

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

**EDUCATION**

1958	M.B.B.Ch.*University of Witwatersrand Johannesburg, R.S.A.
1964	M.R.C.O.G. Royal College of Obstetricians and Gynecologists, London, England
1968	M.D.**University of Witwatersrand Johannesburg, R.S.A.
1977	Ph.D.***University of Stellenbosch Bellville, R.S.A.

\* U.S. equivalent: M.D.  
\*\* U.S. equivalent: Ph.D.  
\*\*\* Same

**TRAINING**

**Internship**

01/01/59 - 06/30/59	Medical Internship Grey's Hospital Pietermaritzburg, R.S.A.
07/01/59 - 12/31/59	Surgical Internship King Edward VIII Hospital University of Natal Durban, R.S.A.

**Residency Training**

04/01/60 - 12/63	OB/GYN Residency King Edward VIII Hospital University of Natal Durban, R.S.A.
------------------	--

**College Fellowships**

06/07/78	F.R.C.O.G. - Elected a Fellow of the Royal College of Obstetricians and Gynecologists, by peer recognition.
06/30/78	F.A.C.O.G. - Elected a Fellow of the American College of Obstetricians and Gynecologists, by examination.

**PROFESSIONAL EXPERIENCE**

**Academic**

Department of Obstetrics and Gynecology  
King Edward III Hospital and  
University of Natal, Durban, R.S.A.  
Lecturer/Junior Consultant, 1963-1964  
Senior Lecturer/Deputy Head of  
Department/Principal Obstetrician/Gynecologist,  
1964 and 1966-1968

Department of Obstetrics and Gynecology  
Addington Hospital, Durban, R.S.A.  
Chairman, 1969-1972

Department of Obstetrics and Gynecology  
University of Florida  
College of Medicine, Gainesville, Florida  
Instructor, 01/75 - 12/75.  
Assistant Professor, 01/76 - 09/79.  
Associate Professor, (tenured),  
09/79 - 08/82.  
Professor, 09/82 - 12/85.  
Director of Benign Gynecology,  
09/78 - 06/85.  
Director of Urodynamics Unit,  
09/78 - 12/85.  
Director of Menopause Unit,  
09/78 - 12/85.

Founder & Director,  
The Center for Climacteric Studies at  
The University of Florida  
04/80 - 12/85

Clinical Professor  
Department of Internal Medicine  
University of Florida  
College of Medicine, Gainesville, Florida  
Consultant to Executive Health Center  
04/00 - 06/02

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

**Private Practice**

- a) General (Family) Practice, 10/64 - 06/66
- b) Private Consultant Practice of  
Obstetrics and Gynecology  
in Durban, R.S.A., 10/72 - 12/74
- c) Medical Director,  
Adult Women's Medicine Specialist  
The Women's Medical & Diagnostic Center  
and The Climacteric Clinic, Inc.  
Gainesville, Florida  
09/01/85 - 04/01/97

**Consultant–Lecturer-  
Teacher**

Consultant  
Adult Women's Health & Medicine 4/97 - present

**Private Business**

- a) Founder and President Emeritus  
Women's Medical and Diagnostic Center, Inc.  
222 SW 36th Terrace  
Gainesville, Florida 32607;  
Women's Research Center, Ins., America  
The National Menopause Foundation Inc.  
D.B.A. Women to Woman America, Inc.  
Women's Medical & Diagnostic Center  
1015 S.E. 17th St., Suite 200  
Ocala, FL 34471-3911  
Mid-Life Centers of America, Inc.
- b) Cognifem LLC    Boca Raton Fl  
The goal of this company is to develop and market dietary  
supplements and other therapeutic products Including  
women's health related diagnostic technologies.

**PROFESSIONAL LICENSURE  
and BOARD CERTIFICATION**

State of Florida, No. ME 0029815

**General Practice**

1959 South African Medical and  
Dental Board  
  
1961 General Medical Board, United Kingdom  
  
1977 Florida and Georgia Boards (by examination)  
1977 Flex (by examination)

**Specialist Practice  
(Obstetrics and  
Gynecology)**

1966 South Africa  
  
1966 United Kingdom  
  
1977 United States

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

**VISITING PROFESSOR  
AND CONSULTANT**

Hadassah Hospital, Hebrew University  
Jerusalem, Israel, 12/77

Consultant to Ministry of Health  
Singapore, 8/88

**PROFESSIONAL  
ORGANIZATIONS**

**Past (RSA):**

Child Welfare Association of South Africa

National Executive Committee

Member, Adoption Section

Durban Child Welfare, R.S.A.

Board of Management

National Cancer Association, Natal Branch,

Vice-Chairman of Natal Branch

Gynaecological and Obstetrical Society of

South Africa, Vice-Chairman of Natal Branch

Durban Marriage Guidance Society

Medical Advisor

National Family Planning Association

Natal Branch

**Past & Present \* (USA):**

Association of Professors of Obstetrics and  
Gynecology, Member

Florida Medical Association, Member

Florida Physicians Association, Member

Alachua County Medical Society, Member

Florida Obstetric and Gynecological Society,  
Member

American College of Obstetricians and  
Gynecologists, Member, Fellow 06/30/78 to date \*

Royal College of Obstetrics and Gynecology,  
Member, Fellow 06/07/78 to date \*

International Continence Society, Member

International Menopause Society, Member\*  
Chairman 1981 – 1984

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

Gerontological Society, Member

American Society for Bone and Mineral Research,  
Member

North American Menopause Society, Member

The Royal Society of Medicine, Fellow

**COMMITTEES**

**Past:**

University Senate  
University of Florida, Gainesville  
Representative for the College of Medicine

Sponsored Research 1981 - 1982  
University of Florida, Gainesville Board of Directors

State of Florida Ad Hoc Committee Chairman,  
to advise on the implementation of the requirements  
of the Senate Bill No. 169 providing for a Pap  
smear and breast examination on all female in-patients.

United States Food and Drug Administration  
Invited to testify regarding the suitability, efficacy  
and safety of estrogens as post-coital contraceptives.

United States Congress Office of Technology Assessment  
Advisory Panel on Policy Issues in the Prevention and  
Treatment of Osteoporosis.

United States Congress Office of Technology Assessment  
Advisory Panel on Menopause and Hormone Replacement Therapy:  
Policy and Practice.

Council of Affiliated Menopause Societies—  
An affiliate of the International Menopause Society

1. Project head to develop a uniform standard of  
menopausal care for women world-wide
2. Committee Member. Program for development of curriculum for the  
training of specialists in Climacteric Medicine

**AWARDS AND HONORS**

Andries Blignaut Medal  
Best paper published in the *South African Medical  
Journal* in 1972 for group authorship

Voted into the top 107 providers of women's health care in the U.S.A.  
October 1988 based on Good Housekeeping survey of department of  
obstetric and gynecology heads and senior faculty.

**EDITORIAL  
RESPONSIBILITIES**

- Present :** Senior editorial Advisor: *Maturitas*. An International Journal of Midlife Health and Beyond.
- Past :** Editorial Board: *Maturitas* - an international multi-disciplinary journal concerned with the medical, sociological and psychological aspects of life in the middle years.
- Editorial Board: *Menopause Management*  
Published by The Conwood Group, Inc.
- Editorial Board: Women's Health Watch  
Published by *The Female Patient*
- Editor: *Transition: A Journal of Climacteric Medicine*.
- Section Editor: *Menopause*  
The Journal of the North American Menopause Society
- Publisher: *Women's Health Digest*  
222 SW 36th Terrace, Gainesville, Florida
- Editorial Board: *The Female Patient*
- Editor: *Midlife Wellness* - Journal of the Center for Climacteric Studies.
- Editor: *Midpoint*  
Published by Macmillan Publishers
- Series Editor: *Menopausal Update*  
Published by Parke-Davis
- Guest Editor: *Clinical Obstetrics and Gynecology* - Climacteric and Osteoporosis, Volume 30, Number 4, December 1987.
- Editor: The Climacteric: *Contemporary OB/GYN*,  
September, 1984, 93-118.
- Consultant: *Revisiones en Revista*  
Iberoamericana de Menopausia

**MEDICAL ADVISORY BOARDS  
AND CONSULTANT**

- Past :**
1. Advanced Care (Division of Johnson & Johnson)
  2. Ayerst Corporation
  3. Bayer
  4. Berlex Laboratories, Inc.
  5. Bristol-Myers Squibb
  6. CompuMed, Inc.
  7. Kelly Group
  8. Mead Johnson Laboratories
  9. Merck (Darmsdadt, Germany)
  10. Merk (USA)
  11. Novo Nordisk\* (Copenhagen)
  12. Organon Inc.
  13. Parke-Davis
  14. Pharmacia (Stockholm)
  15. Pharmacia Upjohn
  16. Procter & Gamble
  17. Rhône-Poulenc-Rorer
  18. Sano Corporation
  19. Schering (Berlin)
  20. Solvay Pharmaceuticals, Inc.
  21. Strakan Pharmaceuticals
  22. Demetech

## **PUBLICATIONS**

### **Thesis**

1. The Pregnant Natal Indian Diabetic With Chapter on Carbohydrate Metabolism. Thesis for the Degree of Doctor of Medicine of The University of Witwatersrand. Johannesburg, RSA 1968 (384 pages)
2. Insulin Metabolism in the Pregnant Natal Indian Diabetic. Thesis for the Degree of Doctor of Philosophy in Medicine of The University of Stellenbosch, RSA 1975 (450 pages)

### **Books: Professional and Consumer Education**

1. *The Great Debate: Abortion in the South African Context.*  
Eds., G.C. Oosthuizen, G. Abbot, and M. Notelovitz.  
Howard Timmins Publishers, Cape Town, R.S.A., 1974.
2. *Stand Tall! Every Woman's Guide to Preventing Osteoporosis.*  
M. Notelovitz and M. Ware.
  - A. English Edition: Triad Publications, Gainesville, Florida, U.S.A., 1982.  
Bantam Books, March 1985.
  - B. German Edition: Aufrecht bis inshobe Alter, Publisher, Goldmann Ratgaber, 1984.
  - C. Japanese Edition: 1987
  - D. Second Edition: With D. Tonnessen and M. Ware (1998)
3. *The Climacteric in Perspective: Proceedings of the Fourth International Congress on the Menopause.*  
M. Notelovitz and Peter Van Keep.  
MTP Press, Lancaster, 1986.
4. *Physiological Hormone Replacement Therapy: Significant Clinical Developments in the Management of the Menopause.*  
Proceedings of a Symposium held at the Sixth International Congress on the Menopause, Bangkok, October 1990.  
Eds., N. Dusitsin and M. Notelovitz.  
The Parthenon Publishing Group Ltd., Lancs, UK, 1991.
5. *Menopause and Midlife Health.*  
M. Notelovitz and D. Tonnessen.  
St. Martin's Press, New York, 1993.
6. *Estrogen: Yes or No?*  
M. Notelovitz and D. Tonnessen.  
St. Martin's Press, New York, 1993.
7. *Osteoporosis: Prevention, Diagnosis and Management.*  
M. Notelovitz.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

Professional Communications, Inc., Oklahoma, 1994 (first edition);  
1997 (2<sup>nd</sup> edition)  
1999 (3<sup>rd</sup> edition)  
2002 (4<sup>th</sup> edition)  
2008 ( 5<sup>th</sup> edition)

8. *The Essential Heart Book for Women.*  
M. Notelovitz and D. Tonnessen.  
St. Martin's Press, New York, 1995.
9. *Health Plan for the Adult Woman*  
M.H.Birkhaeuser, Balow DH,Notelovitz M,Rees MC.  
Taylor and Francis, London and New York 2005

**Contributions to Books**

1. Abortion and Responsible Cohabitation.  
M. Notelovitz  
In: *The Great Debate: Abortion in the South African Context.*  
Eds., G.C. Oosthuizen, G. Abbot, and M. Notelovitz.  
Howard Timmins Publishers, Cape Town, R.S.A., 1974.
2. Evaluation of the Cardiovascular Risks of Hormone Replacement in the Menopause.  
M. Notelovitz.  
In: *Gynecology and Obstetrics*, Proceedings of the 9th World Congress of Gynecology and Obstetrics, Tokyo, October 25 - 31, 1979.  
Eds., S. Sakamoto, S. Tojo, and T. Nakayama.  
Excerpta Medica, Elsevier North-Holland, 1979.
3. Fetal Cerebral Blood Flow and Metabolism.  
R.M. Abrams, M. Notelovitz, and J.F. Clapp.  
In: *Circulation in the Fetus Newborn.*  
Eds., L.D. Longo and D.D. Reneau.  
Raven Press, New York, 1979.
4. The Single-Unit Delivery System: Obstetric Unit Design for the 1980's.  
M. Notelovitz.  
In: *Hospital Special Care Facilities: Planning for User Needs.*  
Ed., H. Laufman.  
Academic Press, New York, 1981.
5. Coagulation Risks with Postmenopausal Estrogen Therapy.  
M. Notelovitz and M. Ware.  
In: *Progress in Obstetrics and Gynecology.*  
Ed., J. Studd.  
Churchill, Livingstone, Edinburgh, 1982. Page 228.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

6. Progestins in the Peri-Menopause.  
M. Notelovitz.  
In: *The Controversial Climacteric*.  
Eds. P.A. VanKeep, W.H. Utian, and A. Vermeulen.  
MTP Press Limited, Lancast, UK, 1982. Page 127.
7. Schistosomiasis of the Female Genital Tract.  
M. Notelovitz.  
In: *Infectious Disease in Obstetrics and Gynecology*, 2nd Edition.  
Ed., G.R.G. Monif.  
Harper & Row, Philadelphia, 1982.
8. The Climacteric (Special Series).  
M. Notelovitz, Series Editor.  
*Contemporary OB/GYN* September, 1984, 93-118.
9. Dilation and Curettage.  
M. Notelovitz.  
In: *Mastery of Surgery*.  
Eds., L.M. Nyhus and R.J. Baker.  
Little, Brown and Company, Boston, 1984. Page 1165, Volume II.
10. Dilation and Curettage.  
M. Notelovitz.  
In: *Mastery of Surgery*, 2nd Edition.  
Eds., L.M. Nyhus and R.J. Baker.  
Little, Brown and Company, Boston, 1992. Page 1491, Volume II.
11. Early Diagnosis of Osteoporosis.  
M. Notelovitz.  
In: *The Climacteric: An Update*.  
Eds. H. & B. Van Herendale, F.E. Riphagen, L. Goessens and H. Vandel Pas.  
MTP Press Limited, Lancaster, UK, 1984. Page 181.
12. Management of Postmenopausal Women.  
M. Notelovitz, and M. Ware.  
In: *Current Geriatric Therapy*.  
Eds., T. Covington, J.I. Walker.  
Saunders, New York, 1984. Page 405.
13. Oral Contraception and Coagulation.  
M. Notelovitz.  
In: *Clinical Obstetrics & Gynecology*. 28:73, 1985.  
Series Ed. C.P. Weiner.
14. The Influence of Nutrition and Exercise.  
M. Notelovitz.  
In: *A Modern Approach to the Perimenopausal Years*.  
Ed. R.B. Greenblatt.  
De Gruyter, Berlin, 1986. Pages 109-116.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

15. Interrelations of Exercise and Diet on Bone Metabolism and Osteoporosis.  
M. Notelovitz.  
In: *Nutrition and Exercise*.  
Ed. Myron Winick.  
John Wiley & Sons, Inc., New York, 1986. Pages 203-227.
16. Menopause and the Climacteric.  
M. Notelovitz.  
In: *Scientific Foundations of Obstetrics & Gynecology*, 3rd Edition.  
Eds., E. Philipp, J. Barnes, and M. Newton.  
Heinemann, London, 1986. Pages 197-207.
17. Alternatives to Hormonal Therapy.  
M. Notelovitz.  
In: *Gynecology and Obstetrics - Proceedings of the XIth World Congress in Berlin*.  
Eds. K. Thomsen and H. Ludwig.  
Springer-Verlag, Berlin.
18. How to Identify the Woman at Risk and How to Identify the Patient.  
M. Notelovitz.  
In: *Osteoporosis 1987*.  
Eds. C. Christiansen, J.S. Johansen, B.J. Riis.  
Osteopress Aps., Copenhagen, 1987. Pages 1197-1204.
19. Osteoporosis and the Gynecologist.  
M. Notelovitz.  
In: *Osteoporosis: Current Concepts*. Report of the Seventh Ross Conference on Medical Research.  
Ed. Roche A.F. Columbus, Ohio, Ross Labs, 1987. Pages 50-55.
20. The Menopause.  
M. Notelovitz.  
In: *Women and Exercise: Physiology and Sports Medicine*.  
Eds. M. Shangold and G. Mirkin.  
F. A. Davis Company, Philadelphia, 1988. Pages 156-177.
21. Menopause.  
M. Notelovitz and M.M. Shangold.  
In: *Women and Exercise: Physiology and Sports Medicine*, 2nd Edition.  
Eds. M.M. Shangold and G. Mirkin.  
F. A. Davis Company, Philadelphia, 1994. Pages 187-213.
22. Non-Hormone Treatment of the Menopause.  
In: *The Menopause*.  
Eds. M. Whitehead & J. Studd.  
Blackwell Scientific Publications, Oxford, 1988. Pages 102-115.
23. Exercise and Cognitive Function in the Menopause.  
In: *Premenstrual, Postpartum, and Menopausal Mood Disorders*.  
Eds. L.M. Demers, J.L. McGuire, A. Phillips and D.R. Rubinow.  
Urban & Schwarzenberg, Inc., Baltimore, 1989. Pages 205-212.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

24. Exercise and Health Maintenance in Menopausal Women.  
M. Notelovitz.  
In: *Multidisciplinary Perspectives on Menopause*.  
Eds. M. Flint, F. Kronenberg and W. Utian.  
Annals of the New York Academy of Sciences, 592:204-220, 1990.
25. Is There a Need for Menopause Clinics?  
M. Notelovitz  
In: *Multidisciplinary Perspectives on Menopause*.  
Eds. M. Flint, F. Kronenberg and W. Utian.  
Annals of the New York Academy of Sciences, 592:239-241, 1990.
26. Lifestyle, Exercise and Osteoporosis.  
M. Notelovitz.  
In: *HRT and Osteoporosis*, Chapter 24, pp 323-347, 1990.  
Eds. J.O. Drife and J.W.W. Studd.  
Springer-Verlag.
27. Lipids and lipoproteins in postmenopausal women: effect of route of estrogen administration and aerobic exercise.  
M. Notelovitz, E. Feldman, S. Larsen and F. Khan.  
Presented at the Third International Symposium on Osteoporosis, Copenhagen, Denmark, October 14-20, 1990.  
In: *Osteoporosis 1990*, Volume 3, Session 7, pp 1822-1825.  
Eds., C. Christiansen and K. Overgaard.  
Osteopress ApS, Denmark, 1990.
28. Health Concerns of the Postmenopausal Woman.  
M. Notelovitz.  
Presented at the Syntex Annual Women's Healthcare Roundtable. Monograph, 1991, pp 213-235.
29. The Modifying Influence of Lifestyle on the Metabolic Effects of Hormone Replacement Therapy.  
M. Notelovitz & F.Y. Khan.  
Presented at the Proceedings of the Novo Nordisk Symposium, Cardiovascular Effects of Hormone Replacement Therapy, February 1-2, 1991.
30. Oral Contraceptives: Effect on Hemostasis.  
M. Notelovitz.  
In: *Contraception*, Chapter 5.  
Eds., D. Shoupe and F.P. Haseltine.  
Springer-Verlag New York, Inc., New York, 1993. Pages 42-59.
31. Hormone Therapy and Hemostasis  
M. Notelovitz.  
In: *Treatment of the Postmenopausal Woman: Basic and Clinical Aspects*, Chapter 25.  
Ed., R.A. Lobo.  
Raven Press Ltd., New York, 1994. Pages 271-281.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

32. Bone  
M. Notelovitz.  
In: *Pharmacology of the Contraceptive Steroids*, Chapter 16.  
Chief Ed., J.W. Goldzieher.  
Associate Ed., K. Fotherby.  
Raven Press, Ltd., New York, 1994. Pages 259-269.
33. Non-hormonal management of the menopause.  
M. Notelovitz.  
In: *The Modern Management of the Menopause: A Perspective for the 21st Century - The Proceedings of the VIIth International Congress on the Menopause*, Stockholm, Sweden, 1993.  
Eds. G. Berg and M. Hammar.  
The Parthenon Publishing Group, London, 1994. Pages 513-523.
34. Hormone Therapy and Hemostasis  
M. Notelovitz  
In: *Treatment of the Postmenopausal Woman*, 2nd Edition, Chapter 36.  
Editor: R. A. Lobo  
Lippincott-William & Wilkens, Publishers, Philadelphia, PA, 1999. Page 397
35. Integrated Adult Women's Medicine: A Model for Women's Healthcare  
M. Notelovitz  
In: *Treatment of the Postmenopausal Woman*, 2nd Edition, Chapter 5825.  
Editor: R. A. Lobo  
Lippincott-William & Wilkens, Publishers, Philadelphia, PA, 1999. Page 621
36. Menopause.  
M. Notelovitz  
In: *Endocrinology of Aging. Contemporary Endocrinology*  
Editors: Van Den Berg, J. E. Morley  
Humana Press, Totowa, NJ
37. Transdermal Estrogen Therapy and the Risk of Breast Cancer: a Clinical Appraisal.  
M. Notelovitz  
In: *Hormone Replacement Therapy and Cancer*  
Editors: A. R. Genazzani  
Parthenon Publishing, Lancaster, UK, 2002, pg 41.
38. Can Exercising Prevent or Delay Aging? The Biologic Principles.  
M. Notelovitz  
In: *Menopause: State of the Art*.  
IMS Congress, Berlin, June 2002.  
Ed. H.P.G. Schneider.  
Parthenon Publishing. Lancaster UK
39. The Adult Women's Health Plan  
M. Notelovitz  
In: *Menopause: State of the Art*.  
IMS Congress, Berlin, June 2002.  
Ed. H.P.G. Schneider.  
Parthenon Publishing. Lancaster UK

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

40. Pharmacology During the Menopausal Transition  
M. Notelovitz  
In: Climacteric Medicine – Where do we go?  
Eds. H.P.G.Schneider & F.Naftolin  
Taylor & Francis,London & New York,2005,pgs 110-119
41. Hormone Therapy and Hemostasis  
M. Notelovitz  
In: *Treatment of the Postmenopausal Woman*, 3<sup>rd</sup> Edition  
Editor: R.A.Lobo  
Lippincott-William & Wilkens,Publishers,Philadelphia,PA,2007, page 481.
42. Integrated Adult Women’s Medicine: A Model for Women’s Healthcare  
M. Notelovitz  
In: *Treatment of the Postmenopausal Woman*, 3<sup>rd</sup> Edition  
Editor: R.A.Lobo  
Lippincott-William & Wilkens, Publishers,Philadelphia,PA. 2007, page 853.

**Monographs**

1. Diabetes and Pregnancy - Theory and Practice: Current Problems in Obstetrics and Gynecology.  
M. Notelovitz and W. Quinlan.  
Year Book Medical Publishers, 1980.
2. New Understandings of the Physiology and Anatomy of Labor as Applied to Family-Centered Care.  
M. Notelovitz.  
The Cybele Society, 1982.
3. Cardiovascular Disease in Post-Menopausal Women: A Practical Management Manual for Primary Care Providers.  
M. Notelovitz.  
Novo Nordisk, 1991.
4. Clinical Implications of Androgens in Surgical Menopause.  
Nachtigall LE, Notelovitz M, Simon JA

**Abstracts**

1. Stress Management and Aging in Women.  
J.L. Resnick, M.C. Dougherty, and M. Notelovitz.  
Paper presented in Poster Session, American Psychological Association,  
Anaheim, California, 1983.
2. Assessment of Patient and Physician Knowledge about Osteoporosis -  
Abstract No. 110.  
C. Rector, B. Cook, J. Krischer, and M. Notelovitz.  
4th International Congress on the Menopause, November 1984.  
*Maturitas* 1984;6:168.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

3. Comparison of Single Photon Absorptiometry of the Radius with Absorptiometry of the Phalanges - Abstract No. 173.  
L. McKenzie, R. Tesar, J. Pendergast, M. Notelovitz, R. Bachtell and C. Colbert.  
4th International Congress on the Menopause, November 1984.
4. Consideration for Calcium Balance: A Dietary Calcium Prevention Program for Post-Menopausal Women - Abstract No. 146.  
R. Tesar, E. Shim, and M. Notelovitz.  
4th International Congress on the Menopause, November 1984.  
*Maturitas* 1984;6:146.
5. Effect of Loadbearing During Treadmill Walking in Women age 57-67 years - Abstract No. 23.  
K. Caramelli and M. Notelovitz.  
4th International Congress on the Menopause, November 1984.  
*Maturitas* 1984; 6:95.
6. The Effect of Three Exercise Treatments on the Cardiovascular Fitness of Sedentary Post-Menopausal Women - Abstract No. 43.  
C. Fields, K. Caramelli, Y. Suggs, W. Harris, K. Dunn, and M. Notelovitz.  
4th International Congress on the Menopause, November 1984.  
*Maturitas* 1984;6:112.
7. The Metabolic Effects of 25 mg and 50 mg 17-Beta Estradiol Pellet Therapy in Surgically Menopausal Women - Abstract No. 174.  
M. Johnston, S. Smith, S. DeVine, I. Levinson, and M. Notelovitz.  
4th International Congress on the Menopause, November 1984.
8. A Mobile Unit for Osteoporosis Screening - Abstract No. 172.  
C. Rector, B. Cook, M. Notelovitz, and J. Krischer.  
4th International Congress on the Menopause, November 1984.
9. Significant Life Events and Sources of Stress in Healthy Climacteric Women.  
J.L. Resnick, M.D. Dougherty, and M. Notelovitz.  
4th International Congress on the Menopause, November 1984.
10. Single Photon Absorptiometry - A Valid Method for Detecting Osteopenia - Abstract No. 145.  
R. Tesar, M. Notelovitz, and W. Harris.  
4th International Congress on the Menopause, November 1984.  
*Maturitas* 1984; 6:107.
11. Influence of Osteoporosis on the Progression of Periodontal Disease.  
S.B. Low, M. Chanatry, R.L. Rogers, and M. Notelovitz.  
International and American Association for Dental Research, March 21-24, 1985.
12. Cardiorespiratory Response to One Year of Aerobic Exercise or Strength Training in Post-Menopausal Women.  
C. Fields, C.W. Zauner, A.D. Martin and M. Notelovitz.  
Poster. American Physiology Society, New Orleans, 1986.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

13. Maximal Oxygen Uptake, Body Weight and Bone Mineral Density in Post-Menopausal Women.  
D. Martin, M. Notelovitz, C. Fields.  
*Med Sci Sports Exerc*, 1987;19:(suppl-2) S13.
14. Trabecular Bone Density of Postmenopausal Lacto-Ovo-Vegetarian and Omnivorous Women.  
R. Tesar, M. Notelovitz, E. Shim, and G. Kauwell.  
The American Dietetic Association, San Francisco, October 3-7, 1988.
15. Endothelin-I Levels in Healthy Postmenopausal Women.  
R. Lobo, M. Notelovitz, F. Khan, A. Vijod, F. Stanczyk L. Parker-Botelho.  
*Soc Gynecol Invest*, November 1990.
16. Comparison of Techniques for Measuring Body Composition in Women: Influence of Age and Fatness.  
M. Notelovitz, M. Pollock, J. Graves, F. Khan and L. Garzarella.  
American College of Sports Medicine, Annual Meeting, 1991.
17. Effect of Long-Term Treatment with Oral Esterified Estrogens (estrone sulphate + equilin sulphate) on Cholesterol and Lipoprotein Levels in Postmenopausal Women.  
M. Notelovitz, N. Watts, C. Timmons, A. Addison, B. Wiita, and L. Downey.  
The North American Menopause Society, 2nd Annual Meeting, 1991.
18. Effects of Oral Esterified Estrogens and Esterified Estrogens + Androgens on Bone Mineral Density in Postmenopausal Women.  
N. Watts, M. Notelovitz, C. Timmons, A. Addison, B. Wiita, and L. Downey.  
The North American Menopause Society, 2nd Annual Meeting, 1991.
19. Influence of Extended Treatment with Oral Estrogen/Androgen Combination on Lipids and Lipoproteins in Surgically Menopausal Women.  
M. Notelovitz, N. Watts, C. Timmons, A. Addison, B. Wiita, and L. Downey.  
The North American Menopause Society, 2nd Annual Meeting, 1991.
20. Effects of Estrogen + Low Dose Androgen vs. Estrogen Alone on Menopausal Symptoms in Oophorectomized/Hysterectomized Women.  
M. Notelovitz, N. Watts, C. Timmons, A. Addison, B. Wiita, and L. Downey.  
The North American Menopause Society, 3rd Annual Meeting, 1992.
21. Long Term Safety of Estrogen + Low Dose Androgen vs. Estrogen Alone in Menopausal Women.  
N. Watts, L. Speroff, M. Notelovitz, C. Timmons, A. Addison, B. Wiita, and L. Downey.  
The North American Menopause Society, 3rd Annual Meeting, 1992.
22. Menopause Clinics: Technology And The Basis For The Practice Of Climacteric Medicine.  
M. Notelovitz.  
The North American Menopause Society, 3rd Annual Meeting, 1992.
23. Effects of Supervised Versus At-Home Exercise in the Treatment of Obesity.  
M.G. Perri, A.D. Martin, S.B. Sears, E.A. Leermakers and M. Notelovitz.  
Proceedings of The Society of Behavioral Medicine's Fourteenth Annual Scientific Sessions, March 10-13, 1993, San Francisco, California.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

24. Urinary N-Telopeptide of Type I Collagen Monitors Bone Resorption and May Predict Change in Bone Mass of the Spine in Response to Hormone Replacement Therapy. I. Campodarve, U. Ulrich, N. Bell, G. Clark, B. Drinkwater, S. English, C. Johnston, M. Notelovitz, C. Rosen, N. Mallinak, D. Cain, K. Flessland, C. Chesnut. The 17th Annual Meeting of The American Society for Bone and Mineral Research (ASBMR), September 9-13, 1995, Baltimore, Maryland.
25. Local Versus Systemic Effects of an Estradiol Releasing Vaginal Ring. G.A. Bachmann, L. Nachtigall, M. Notelovitz, L. Birgersson, C. Dvergsten, E. Kemmann, Dept. of OB/GYN, WMDNJ - Robert Wood Johnson Medical School, Dept. of OB/GYN, NY University Medical Center, Women's Medical Diagnostic Center, Pharmacia, Inc. The American Society of Reproductive Medicine (ASRM), March 1996.
26. Low Dose Esterified Estrogens (Estratab) Reduce Biochemical Markers of Bone Metabolism and Increase Vertebral BMD in Postmenopausal Women. N. Watts, M. Greenwald, M. Notelovitz, H. Genant, J. Lenihan, H.M. Yang, J. Nolan, The Emory Clinic, Atlanta, GA, Osteoporosis Medical Ctr., Rancho Mirage, CA, The Climacteric Clinic, Gainesville, FL, UCSF, San Francisco, CA, PC, Tacoma, WA, Solvay Pharm., Marietta, GA, for the Estratab Osteoporosis Study Group. The 18th Annual Meeting of The American Society for Bone and Mineral Research (ASBMR), September, 1996, Seattle, Washington.
27. Use of NTx Levels in the Clinical Management of Hormone Replacement Therapy in Early Postmenopausal Women. N. Bell, G. Clark, B. Drinkwater, S. English, C. Johnston, M. Notelovitz, C. Rosen, N. Mallinak, D. Cain, K. Flessland, M. Pettinger, C. Chesnut. The 18th Annual Meeting of The American Society for Bone and Mineral Research (ASBMR), September, 1996, Seattle, Washington.
28. Norethindrone Acetate at 0.5 mg Dose Adds to the Efficacy of 1 mg 17-Estradiol on Vasomotor Symptom Relief. Notelovitz M, Arce JC, Nanavati N, Huang WC. North American Menopause Society, Toronto, June\_1998
29. One mg 17-Estradiol is the Optimal Dose for Treatment of Moderate to Severe Vasomotor Symptoms: A Dose-Response Study. Notelovitz M, Arce JC, Nanauati N, Huang WC. North American Menopause Society, Toronto, June 1998
30. Management of the Late Menopause: Low Dose Adjustive Hormone Therapy. Notelovitz M. Third International Symposium. Women's Health and Menopause. Florence, Italy, June 13-16, 1998

## Journal Articles

### Hormone Therapy and Menopause

1. Effect of Natural Oestrogen on Coagulation. (Letter).  
M. Notelovitz; Greig HB  
*Br Med J* 1974;3:171.
2. Metabolic Effect of Conjugated Oestrogens (USP) on Glucose Tolerance.  
M. Notelovitz.  
*S Afr Med J* 1974;48:2599-2603.
3. Metabolic Effect of Conjugated Oestrogens (USP) on Lipids and Lipoproteins.  
M. Notelovitz and B. Southwood.  
*S Afr Med J* 1974;48:2552-2556.
4. The Effect of Natural Oestrogen on Blood Pressure and Weight in Postmenopausal Women.  
M. Notelovitz.  
*S Afr Med J* 1975;49:2251-2254.
5. The Effect of Natural Oestrogens on Coagulation.  
M. Notelovitz and H.B.W. Grieg.  
*S Afr Med J* 1975;49:101-105.
6. Natural Oestrogen and the Antithrombin III Level. (Letter).  
M. Notelovitz.  
*Lancet* 1975;1:412.
7. Letter: Effect of replacement therapy with natural oestrogens on blood clotting.  
Notelovitz M.  
*Br Med J* 1975 Dec 27;4(5999):756-7.
8. Natural Estrogen and Antithrombin III Activity in Post-Menopausal Women.  
M. Notelovitz and H.B.W. Greig.  
*J Reprod Med* 1976;16:87-90.
9. The effect of long-term estrogen replacement therapy on glucose and lipid metabolism in postmenopausal women.  
Notelovitz M.  
*S Afr Med J* 1976 Nov 20;50(50):2001-3.
10. Coagulation, Oestrogen, and the Menopause.  
M. Notelovitz.  
*Clin Obstet Gynecol* 1977;4:107-128.
11. Gynecological Problems of Menopausal Women: Part I - Changes in Genital Tissue. (Non-Review).  
M. Notelovitz.  
*Geriatrics* 1978;33:24-30.
12. Gynecological Problems of Menopausal Women: Part II - Treating Estrogen Deficiency (Non-Review).  
M. Notelovitz.  
*Geriatrics* 1978;33:35-42.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

13. Gynecological Problems of Menopausal Women: Part III - Changes in Extra-genital Tissues and Sexuality.  
M. Notelovitz.  
*Geriatrics* 1978; 33:51-57.
14. The Menopause and Its Treatment.  
M. Notelovitz.  
*J.Fla Med Ass* 1978; 65:341-344.
15. When and How to Use Estrogen Therapy in Women Over 60.  
M. Notelovitz.  
*Geriatrics* 1980;35:113.
16. Menopause: When to Treat. (Non-Review).  
M. Notelovitz.  
*Hospital Medicine* October 9, 1980.
17. Guidelines for Rational Treatment of Postmenopausal Women: The Estrogen Controversy in Perspective.  
T.A. Tartaglione, P.L. Doering, O.E. Araujo, and M. Notelovitz.  
*U.S. Pharmacist* 1981;6:62-71.
18. Interaction Between Estrogen and Dilantin in a Menopausal Woman. (Letter).  
M. Notelovitz, J. Tjapkes, and M. Ware.  
*N Engl J Med* 1981; 304:788-789.
19. Menopausal Status Is Associated with Increased Inhibition of Blood Coagulation.  
M. Notelovitz, C.S. Kitchens, V. Rappaport, L. Coone, and M. Dougherty.  
*Am J Obstet Gynecol* 1981;141:149-152.
20. Blood Pressure and Body Weight of Naturally Menopausal Women After One Year of Estrogen-Progestin Therapy.  
M. Notelovitz, M.D. Ware, and M.C. Dougherty.  
*Current Therapeutic Research* 1982;31:146.
21. Carbohydrate Metabolism in Relation to Hormonal Replacement Therapy.  
M. Notelovitz.  
*Acta Obstet Gynecol Scand Suppl.* 106:51-56, 1982.
22. Prolactin: Effects of Age, Menopausal Status, and Exogenous Hormones.  
M. Notelovitz, M.D. Ware, D. Buhi, and M.C. Dougherty.  
*Am J Obstet Gynecol* 1982;143:225-227.
23. Vaginal Blood Flow Response to Exogenous Estrogen in Surgical Menopausal Women.  
R.M. Abrams, H. Stanley, R. Carter, and M. Notelovitz.  
*Am J Obstet Gynecol* 1982;143:375-378.
24. Combination Estrogen and Progestogen Replacement Therapy Does Not Adversely Affect Coagulation.  
M. Notelovitz, C. Kitchens, K. Hirschberg, M. Ware, and L. Coone.  
*Obstet Gynecol* 1983;62:596-600.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

25. Lipids and Lipoproteins in Women After Oophorectomy and the Response to Oestrogen Therapy.  
M. Notelovitz, J.C. Gudat, M.D. Ware, and C. Dougherty.  
*Br J Obstet Gynaecol* 1983;90:171-177.
26. Oestrogen-Progestin Therapy and Lipid Balance of Post-Menopausal Women.  
M. Notelovitz, J.C. Gudat, M.D. Ware, and M.C. Dougherty.  
*Maturitas* 1982;4:301-308.
27. Prolactin, Hormone Replacement Therapy, and Breast Cancer. (Letter).  
M. Notelovitz.  
*Am J Obstet Gynecol* 1983;146:740-741
28. Coagulation and Fibrinolysis in Estrogen Treated Surgically Menopausal Women.  
M. Notelovitz, C. Kitchens, and L. Coone.  
*Obstet Gynecol* 1984;63:621-625.
29. The effects of benzodiazepines on hormones in women with idiopathic hirsutism.  
Dennerstein L, Callan A, Warne G, Montalto J, Brown J, Burrows G, Fulton A, Notelovitz M.  
*Prog Neuropsychopharmacol Biol Psychiatry*. 1984;8(1):11-7
30. Serum Hormone Levels in Men Exposed to Vaginal Estrogen Cream: A Preliminary Report.  
M. Ware, E. Kennedy Thomas, M. Notelovitz.  
*Maturitas* 1985;7:373-376.
31. Commentary: Steroids and Thromboembolic Disease.  
M. Notelovitz.  
*J Reprod Med* 1986 June;31:(6)555-556
32. Estrone vs estradiol: an examination of relative carcinogenic potential.  
Notelovitz M.  
*Int J Fert* 1986;31(3 suppl [ESTROGEN])35-8. Review. No abstract available.
33. Metabolic and Hormonal Effects of 25-mg and 50-mg 17-Estradiol Implants in Surgically Menopausal Women.  
M. Notelovitz, M. Johnston, S. Smith, C. Kitchens.  
*Obstet Gynecol* 1987;70(5):749-754.
34. Is Routine Use of Estrogen Indicated in Postmenopausal Women? An Opposing View.  
M. Notelovitz.  
*J Fam Pract* 1989;29(4):410-415.
35. Progestins and Coagulation.  
M. Notelovitz.  
Consensus Development Conference on Progestins.  
*International Proceedings Journal* 1, #1:229-234, April, 1989.
36. Hormonal Therapy in Climacteric Women: Compliance and its Socioeconomic Impact.  
M. Notelovitz.  
Women's Health, Proceedings of the National Conference on Women's Health Series Special Topic Conference on Osteoporosis, October 30, 1987, Bethesda, Maryland.  
*Public Health Rep* September-October 1989;104 suppl:70-75.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

37. Estrogen Replacement Therapy: Indications, Contraindications, and Agent Selection.  
M. Notelovitz.  
*Am J Obstet Gynecol* 1989;161(6), Part 2:1832-1541.
38. Effect of Cyclic Estrone Sulfate Treatment on Lipid Profiles of Postmenopausal Women With Elevated Cholesterol Levels.  
M. Notelovitz, S. Katz-Karp, D. Jennings, J. Lancaster, E. Green, and R. Stoll.  
*Obstet Gynecol* 1990;76(1):65-70.
39. Hormone Replacement Therapy in the Prevention of Cardiovascular Disease.  
M. Notelovitz.  
*Postgrad Med* 1990 August 22;A Special Report: 21-32.
40. Cardiovascular Health in Postmenopausal Women.  
M. Notelovitz.  
Proceedings of "Climacteric and the Menopause" Sessions 1990 July; Complutense University, Madrid, Spain.  
*Acta Ginecologica*, XLVIII(8):329-346, October 1991.
41. A Double-Blind Evaluation of Transdermal Oestradiol (Menorest) versus Placebo in the Treatment of Postmenopausal Symptoms.  
Notelovitz M, G. Bachman, D. Lucking.  
*European Journal of Clinical Research*, May 1996
42. Hormone Replacement Therapy--Benefits Versus Risks.  
M. Notelovitz  
*European Menopause Journal* 1996; 3(2):186-196.
43. Minimal Endometrial Proliferation Over a Two-Year Period in Postmenopausal Women Taking 0.3 mg of Unopposed Esterified Estrogens  
M. Notelovitz, R Varner, R. Rebar et al.  
*Menopause* 1997; 7(2);4:80-88.
44. A Comparative Study of Low-Dose Estradiol Vaginal Ring and Conjugated Estrogen Cream for Postmenopausal Urogenital Atrophy.  
G. Bachmann, M. Notelovitz, L. Nachtigall, L. Birgerson.  
1997;4(3);109-115.
45. Urogenital aging:solutions in clinical practice.  
Notelovitz M.  
*Int J Gynaecol Obstet* 1997 Oct;59 suppl 1:S35-9.Review.
46. Clinical experience with a 7-day estrogen patch: Principles and Practice  
M. Notelovitz.  
*Gynecol Endocrinol* 1998;12;1-10.
47. A two year double-blind comparison of estrogen-androgen and conjugated estrogen in surgically menopausal women: Effects on bone mineral density, symptoms and lipids.  
Barrett-Connor E, Young R, Notelovitz M, et al.  
*J Reprod Med* 1999;44:1012-1019

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

48. Discovery and identification of estrogen.  
Notelovitz M.  
*Menopause* 1999 Spring;6(1):2-3. No abstract available.
49. Initial 17-estradiol dose for treating vasomotor symptoms.  
Notelovitz M, Lenihan JP, McDermott M et al.  
*Obstet Gynecol* 2000;95(5):726-731
50. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.  
Notelovitz M, Cassel D, Hille et al.  
*Am J Obstet Gynecol* 2000;182(1):7-12
51. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17--estradiol.  
Notelovitz M, et al.  
*Menopause* 2000;7(5):310-317
52. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women.  
Notelovitz M, John VA, Good WR.  
*Menopause* 2000; No 5, pp 343-353.
53. Urogenital atrophy and low-dose vaginal estrogen therapy.  
Notelovitz M.  
*Menopause* 2000 May-June;7(3):140-2. Review. No abstract available.
54. Estradiol absorption from vaginal tablets in postmenopausal women.  
Notelovitz M, Funk S, Nanavati N, Mazzeo M.
55. The effect of site of application on the transcutaneous absorption of 17 estradiol from a transdermal delivery system (Climara)  
Ellman H, Notelovitz M, Taggart W, Dandekar K.  
*Menopause* 2000;7(5):364-369
56. Does the progestin in oral combination hormone therapy make a difference?  
Notelovitz M.  
*Female Patient* April 2005;30:suppl. 1-8.
57. Androgen effects on bone and muscle.  
Notelovitz M.  
*Fertil & Steril* 2002; 77, Suppl 4: 534-541.
58. Why individualizing hormone therapy is crucial: putting the results of the WHI trial into perspective.  
Notelovitz M.  
*Medscape Women's Health* 2002 Jul-Aug;7(4):9. No abstract available.
59. Female androgen insufficiency: the Princeton consensus statement on definition, classification and assessment.  
Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo R, Notelovitz M, Rosen R, Sarrel P, Sherwin B, Simon J, Simpson E, Shifren J, Spark R, Traish A: Princeton. *Fertile Steril* 2002 Apr;77(4):660-5. Review.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

60. The clinical practice impact of the Women's Health Initiative: political vs biologic correctness.  
Notelovitz M.  
*Maturitas* 2003 Jan 30;44(1):3-9. no abstract available.
61. Hot flashes and androgens: a biological rationale for clinical practice.  
Notelovitz M.  
*Mayo Clin Proc* 2004 Apr;79(4 Suppl):S8-13. Review.
62. Practical recommendations for hormone replacement therapy in the peri- and postmenopause.  
Burger H, Archer D, Barlow D, Birkhaeuser M, Calaf-Alsina J, Gambacciani M, Genazzani A, Hadji P, Iverson OE, Kuhl H, Lobo RA, Maudelonde T, e Castro MN, Notelovitz M, Palacios S, Paszkowski T, Peer E, Pines A, Samsioe G, Stevenson J, Skouby S, Sturdee D, de Villiers T, Whitehead M, Ylikorkala O: Expert Workshop  
*Climacteric* 2004 Jun;7(2):210-6. review. no abstract available.
63. Postmenopausal hormone therapy before and after the Women's Health Initiative study: what consequences?  
Mikkola TS, Clarkson TB, Notelovitz M.  
*Ann Med* 2004;36(6):402-13. Review.
64. The effects of postmenopausal therapies on female sexual functioning: a review of double-blind, randomized controlled trials.  
Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M.  
*Menopause* 2004 Nov-Dec;11(6 Pt 2):749-65. Review.
65. Optimizing women's health: Adult Women's Health and Medicine.  
Notelovitz, M.  
*Climacteric* 2005 Sep;8(3):205-9. No abstract available.
66. Clinical Opinion: The Biologic and Pharmacologic Principles for Age-Adjusted Long-term Estrogen Therapy.  
Notelovitz M.  
*MedGenMed* 2006 mar 28;8(1):84.
67. Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause.  
Notelovitz M.  
*MedGenMed* 2006 Mar 28;8(1):85
68. Should symptomatic menopausal women be offered hormone therapy?  
Lobo RA, Belisle S, Creasman WT, Frankel NR, Goodman NE, Hall JE, Ivey SL, Kingsberg S, Langer R, Lehman R, McArthur DB, Montgomery-Rice V, Notelovitz M, Packin GS, Rebar RW, Rousseau M, Schenken RS, Schneider DL, Sherif K, Wysocki S.  
*MedGenMed* 2006;8(2):1 p preceding 35.
69. Post Menopausal Tibolone Therapy: Biologic Principles and Applied Clinical Practice.  
Notelovitz M.  
*Med Gen Med* 2007;9(1);2

### **Osteoporosis**

1. Thiazide Diuretics and Bone Mineral Loss in Postmenopausal Women.  
P. Davenport, M. McKenzie, M. Notelovitz, L. McKenzie, and J. Pendergast.  
*Am J Obstet Gynecol* 1985;152(6):630-634.
2. Osteoporosis: Its Prevention, Diagnosis and Treatment.  
M. Notelovitz.  
*The Female Patient*, 1986.
3. Post-Menopausal Osteoporosis. A Practical Approach to its Prevention.  
M. Notelovitz.  
*Acta Obstet Gynecol Scand Suppl* 1986;134:67-80.
4. Interrelations of exercise and diet on bone metabolism and osteoporosis.  
Notelovitz M.  
*Curr Concepts Nutr* 1986;15:203-27. Review. No abstract available.
5. Spine and Femur Density Using Dual Photon Absorptiometry in U.S. White Women.  
R. Mazess, H. Barden, M. Ettinger, C. Johnston, B. Dawson-Huges, D. Buran, M. Powell, M. Notelovitz.  
*Bone Miner* 1987;2:211-219.
6. The Role of the Gynecologist in Osteoporosis Prevention: A Clinical Approach.  
M. Notelovitz.  
*Clin Obstet Gynecol* 1987;30:871-882.
7. Serum 25-OHD, Vitamin A and Vitamin E Concentrations in Healthy Finnish and Floridian Women.  
R. Punnonen, M. Gillespy, M. Hahl, T. Koskinen, and M. Notelovitz.  
*Int J Vitam Nutr Res* 1988;58:37-39.
8. Monitoring Skeletal Response to Estrogen.  
R. Mazess, J.C. Gallagher, M. Notelovitz, I. Schiff, and W. Utian.  
*Am J Obstet Gynecol* 1989;161(4):843-848.
9. Axial and Peripheral Bone Density and Nutrient Intakes of Postmenopausal Vegetarian and Omnivorous Women.  
R. Tesar, M. Notelovitz, E. Shim, G. Kauwell, J. Brown.  
*Am J Clin Nutr* 1992;56:699-704.
10. Osteoporosis: screening, prevention, and management.  
M. Notelovitz.  
*Fertil Steril* 1993;59(4):707-725.
11. Comparison of Oral Estrogens and Estrogens Plus Androgen on Bone Mineral Density, Menopausal Symptoms, and Lipid-Lipoprotein Profiles in Surgical Menopause.  
N.B. Watts, M. Notelovitz, M.C. Timmons, W.A. Addison, B. Wiita and L.J. Downey.  
*Obstet Gynecol* 1995;85(4):529-537.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

12. Alternatives to ERT for Osteoporosis and Osteoporotic Fractures.  
M. Notelovitz  
*Contemporary OB/GYN*, November 1996.
13. Estrogen Therapy and Osteoporosis: Principles & Practice  
M. Notelovitz  
*The American Journal of the Medical Sciences* 1997; 313;2-12.
14. Hormone Replacement therapy in Postmenopausal Women: Urinary N-Telopeptide of Type I Collagen Monitors Therapeutic Effect and Predicts Response of Bone Mineral Density.  
C. Chestnut, N. Bell, D.S. Clark, M. Notelovitz et al  
*Am J Med* 1997;102;29-37.
15. Effects of estrogen/androgen therapy on bone mineral density parameters.  
Notelovitz M.  
*J Reprod Med* 2001 Mar;46(3 suppl):325-31. Review.
16. Overview of bone mineral density in postmenopausal women.  
Notelovitz M.  
*J Reprod Med* 2002 Jan;47(1 Suppl):71-81.Review.
17. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy,postmenopausal women.  
Notelovitz M,John VA,Good WR.  
*Menopause* 2002 Sep-Oct;9(5):343-53.

**Exercise**

1. Cardio-Respiratory Efficiency at Submaximal Work in Young and Middle-Aged Women.  
C. Zauner, M. Notelovitz, C.D. Fields, K.M. Clair, W. J. Clair and R. Vogel.  
*Am J Obstet Gynecol* 1984;150:712-715.
2. A Well Woman's Health Maintenance Study Comparing Physical Fitness and Group Support Programs.  
A.A. Gill, V.L. Veigl, J.J. Schuster, and M. Notelovitz.  
*Occupational Therapy Journal of Research* 1984;4:286.
3. Exercise, High-Density Lipoprotein-Cholesterol and Cardiorespiratory Function in Climacteric Women.  
J. Busby, M. Notelovitz, K. Putney, and T. Grow.  
*South Med J* 1985;78(7):769-773.
4. Cardiorespiratory Fitness Evaluation in Climacteric Women: Comparison of Two Methods.  
M. Notelovitz, C. Fields, K. Caramelli, M. Dougherty, A. Schwartz.  
*Am J Obstet Gynecol* 1986;154(5):1009-1013.
5. How Exercise Affects Bone Density.  
M. Notelovitz.  
*Contemp Obstet Gynecol* 1986;27(3):108-116.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

6. The Effect of Low Dose Oral Contraceptives on Cardiorespiratory Function, Coagulation and Lipids, in Exercising Young Women.  
M. Notelovitz, C. Zauner, L. McKenzie, Y. Suggs, T. Grow, and C. Kitchens.  
*Am J Obstet Gynecol* 1987;156:591-598.
7. Exercise, Nutrition and the Coagulation Effects of Estrogen Replacement on Cardiovascular Health.  
M. Notelovitz.  
*Obstet Gynecol Clin North Am* 1987;14:121-141.
8. Effect of Exercise on Glucose Metabolism in Postmenopausal Women.  
S. Van Dam, M. Gillespy, M. Notelovitz, and A.D. Martin.  
*Am J Obstet Gynecol* 1988;159(1):82-86.
9. Predicting Maximal Oxygen Uptake from Treadmill Testing in Trained and Untrained Women.  
A.D. Martin, M. Notelovitz, C. Fields, and J. O'Kroy.  
*Am J Obstet Gynecol* 1989;161(5):1127-1132.
10. Osteoporosis:screening and exercise.  
Notelovitz M.  
*Prog Clin Biol Res* 1989;320:225-52. review. No abstract available.
11. Exercise and health maintenance in menopausal women.  
Notelovitz M.  
*Ann N Y Acad Sci* 1990;592:239-41;discussion 257-62. No abstract available.
12. Estrogen Therapy and Variable Resistance Weight Training Increases Bone Mineral in Surgically Menopausal Women.  
M. Notelovitz, D. Martin, R. Tesar, F.Y. Khan, C. Probart, C. Fields and L. McKenzie.  
*J Bone Miner Res* 1991;6(6):583-90.
13. The Effect of Moderate Aerobic Exercise on Physical Fitness Among Women 70 Years and Older.  
C.K. Probart, M. Notelovitz, D. Martin, F.Y. Khan, C. Fields.  
*Maturitas* 1991;14(1):49-56.
14. Lp(a) Lipoprotein: Relationship To Cardiovascular Disease Risk Factors, Exercise, and Estrogen.  
R.A. Lobo, M. Notelovitz, L. Bernstein, F.Y. Khan, R.K. Ross, W.L. Paul.  
*Am J Obstet Gynecol* 1992;166(4):1182-1190.
15. Effects of Aerobic Training on Bone Mineral Density of Postmenopausal Women.  
D. Martin and M. Notelovitz.  
*J Bone Miner Res* 1993; 8(8):931-936.
16. The Independent Effects of Exercise and Estrogen on Lipids and Lipoproteins in Postmenopausal Women.  
S.R. Lindheim, M. Notelovitz, E.B. Feldman, S. Larsen, F.Y. Khan and R.A. Lobo.  
*Obstet Gynecol* 1994;83(2):167-172.
17. The Effects of Physical Activity on Menopausal Symptoms and Metabolic Changes around Menopause.  
M. Hammar, J. Brynhildsen, Y. Wyon, E. Nedstrand, and M. Notelovitz  
*Menopause: J North Am Menopause Society* 1995;2(4):201-209.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

18. Effects of Group- Versus Home-Based Exercise in the Treatment of Obesity.  
M. Perri, A. Martin, M. Notelovitz, E. Leermakers, S. Sears  
*Journal of Consulting and Clinical Psychology* 1997; 65(2);278-285.

**Innovations in Medical Practice**

1. The Graphic Monitoring of Labor  
M. Notelovitz.  
*S Afr Med J* 1973;47:3-10.
2. Graphic Records in Labor  
M. Notelovitz.  
*Br Med J* 1973;1:50.
3. Commentary: Maternal Position During Labor and Childbirth. (Non-Review).  
M. Notelovitz  
*ICEA Review* 1978;Volume 2, Number 3, 1978.
4. The Single Unit Delivery System - A Safe Alternative to Home Deliveries.  
M. Notelovitz.  
*Am J Obstet Gynecol* 1978;132:889-894.
4. Partograms.  
Notelovitz M.  
*Obstet Gynecol* 1978 Jan;51(1):128. No abstract available.
6. Climacteric Medicine and Climacteric Science. (Editorial, Non-Review).  
M. Notelovitz.  
*Gerontofiles* 1982;5(3).
7. The climacteric center:answering an unmet need. Interview by Leslie Champlin.  
Notelovitz M.  
*Geriatrics* 1982 May;37(5):151-2,156,159. No abstract available.
8. Our Aging Female Population: A Preventive Approach to Their Health Care.  
M. Notelovitz and J. Ingram.  
*J Fla Med Assoc* 1985;72(11):962-966.
9. Climacteric Medicine: Cornerstone for Midlife Health and Wellness.  
M. Notelovitz.  
Proceedings on National Conference on Women's Health (FDA),  
June 17-18, 1986.  
*Public Health Rep* 1987;July-August 102:(4 suppl)116-124.
10. Is there a need for menopause clinics?  
Notelovitz M.  
*Ann N Y Acad Sci* 1990;592:239-41:discussion257-62.No abstract available.
11. An Osteoporosis Education and Screening Program: Results and Implications.  
B. Cook, M. Notelovitz, C. Rector and J. Krischer.  
*Patient Education and Counseling* 1991; 17:135-145.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

12. Reducing Patients' Risk for Coronary Artery Disease: The Role of the OB/GYN.  
M. Notelovitz.  
*Contemp OB/GYN* 1993;38(6):53-70.

**Contraception**

1. Clinical Evaluation of a Normophasic Oral Contraceptive.  
M. Notelovitz and S. Funston.  
*S Afr Med J* 1973;47:1943-1947.
2. Guide to Steroid Contraception in General Practice. (Letter).  
M. Notelovitz.  
*S Afr Med J* 1973;47:2040.
3. Conjugated Estrogen as a Post-Ovulatory Interceptive.  
M. Notelovitz and D. Bard.  
*Contraception* 1978;17:443-454.
4. Contraceptives, Lipids, and Lipoproteins - A Preliminary Report.  
M. Notelovitz, J. Gudat, and L.C. McKenzie.  
*Current Therapeutic Research* 1981;30:627.
5. Estrogens and Postcoital Contraception.  
M. Notelovitz.  
*The Female Patient* 1981;5:36-38.
6. Low Dose Oral Contraceptive Usage and Coagulation.  
M. Notelovitz, C.S. Kitchens, L. McKenzie, L. Coone and R. Carter.  
*Am J Obstet Gynecol* 1981;141:71-75.
7. Low-Dose Oral Contraceptives and Coagulation: Comparison with High-Dose Oral Contraceptives and Intrauterine Devices.  
M. Notelovitz, C. Kitchens, L. Coone, and L. McKenzie.  
*Current Therapeutic Research* 1983;33:207-213.
8. Update on Oral Contraceptives.  
M. Hanson, R.A. Hatcher, D.R. Mishell, Jr., M. Notelovitz, and W.N. Spellacy.  
*J Reprod Med* 1985;30(9):691-713.
9. Oral Contraception and Coagulation.  
M. Notelovitz.  
*Clin Obstet Gynecol* 1985;28(1):73-83.
10. The Effects of Low-Dose Oral Contraceptives on Coagulation and Fibrinolysis in Two High-Risk Populations: Young Female Smokers and Older Premenopausal Women.  
M. Notelovitz, I. Levenson, L. McKenzie, D. Lane, and C.S. Kitchens.  
*Am J Obstet Gynecol* 1985;152(8):995-1000.
11. The use of oral contraceptives past the age of 35:bridging the gap.  
Notelovitz M.  
*Int J Fert* 1988;33 Suppl;13-20.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

12. Lipid and Lipoprotein Changes in Women Taking Low-Dose, Triphasic Oral Contraceptives: A Controlled, Comparative, 12-Month Clinical Trial.  
M. Notelovitz, E. Feldman, M. Gillespy, and J. Gudat.  
*Am J Obstet Gynecol* 1989;160:1269-1280.
13. Effect of Long-Term Triphasic Oral Contraceptive Use on Glucose Tolerance and Insulin Secretion.  
M. Gillespy, M. Notelovitz, A.B. Ellingson, F.Y. Khan.  
*Obstet Gynecol* 1991;78(1):108-114.
14. The Effect of Low-Dose Oral Contraceptives on Lipids and Lipoproteins in Two At-Risk Populations: Young Female Smokers and Older Premenopausal Women.  
M. Notelovitz, I. Levenson, L. McKenzie, F.Y. Khan.  
*Contraception* 1991;44(5):505-516.
15. Changes in Coagulation and Anticoagulation in Women Taking Low-Dose Triphasic Oral Contraceptives: A Controlled Comparative 12-Month Clinical Trial.  
M. Notelovitz, C.S. Kitchens, F.Y. Khan.  
*Am J Obstet Gynecol* 1992;167(5):1255-1261.
16. Contraceptive Efficacy and Safety of a Monophasic Oral Contraceptive Containing 150 µg Desogestrel and 30 µg Ethinyl Estradiol: United States Clinical Experience Using a "Sunday Start" Approach.  
M. Notelovitz.  
*Fertil Steril* 1995; 64(2):261-266.

**Preventive/Diagnostic/Evidence-based Medicine**

1. Assessment of a Rapid Bedside Method for Measuring Blood Urea.  
M. Notelovitz, A.I. Vinik.  
*S Afr Med J* 1970;44:1383-1386.
2. Diabetes Screening During Pregnancy.  
M. Notelovitz.  
*Diabetologia* 1970;6:141-147.
3. Evaluation of a Rapid Bedside Screening Test for Asymptomatic Urinary Tract Infection - A preliminary Communication.  
M. Notelovitz, D.P. de Beer, and J.R.S. Neary.  
*S Afr Med J* 1970; 44:1128-1131.
4. Latent Iron Deficiency Anaemia of Pregnancy.  
M. Notelovitz, M. Nel, and B. Southwood.  
*S Afr Med J* 1972;46:1300-1304.
5. The Uricult Dipslide in Significant Bacteriuria.  
M.J. Bailey, J.T.F. Neary, and M. Notelovitz.  
*S Afr Med J* 1972;46:1323-1326.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

6. Dipslide in Urology. (Letter).  
M. Notelovitz.  
*Br Med J* 1973;1:744.
7. Appraisal of the Uricult dip-slide method in the diagnosis of urinary infections.  
Bailey MJ, Notelovitz M.  
*S Afr Med J* 1973 Jul 7;47(26):1135. No abstract available.
8. The Antenatal Detection of Asymptomatic Disease in Pregnancy.  
M. Notelovitz.  
*S Afr Med J* 1974;48:178-184.
9. Aspiration Curettage and Its Out-Patient Usage.  
D.A.G. Barford and M. Notelovitz.  
*S Afr Med J* 1974; 48:22-24.
10. Asymptomatic Vaginal Disease in Pregnancy.  
M. Notelovitz, P. Massel, and W. Jones.  
*S Afr Med J* 1974;48:803-806.
11. Bacteriuria in Females - Detection, Prevalence, Implication.  
M. Notelovitz.  
*Diagnostica* 1975;35:4.
12. Colposcopy Makes a Successful Comeback. (Non-Reviewed).  
M. Notelovitz, A. Staf, and A.F. Goldfarb.  
*Patient Care* 1976;10:94-99.
13. Using Devices That Measure Bone Mass.  
M. Notelovitz.  
*Contemp Obstet Gynecol Technology* (Special Issue) 1985;24:61-67.
14. Estrogen Therapy in the Management of Problems Associated with Urogenital Ageing: A Simple Diagnostic Test and the Effect of the Route of Hormone Administration.  
M. Notelovitz  
*Maturitas* 1995;22(Suppl):S31-S33.

**Obstetrical Care**

1. Less Conservatism in the Treatment of Eclampsia.  
D. Crichton, M. Notelovitz, and I. Heller.  
*J Obstet Gynaecol Br Comm* 1968;75:1019-1023.
2. Spontaneous Rupture of the Liver During Pregnancy.  
Notelovitz M, Crichton D.  
*S Afr Med J* 1968;42:476-480.
3. Acute Renal Failure Following Quinine Poisoning.  
M. Notelovitz, D. Dalrymple, and M. Funston.  
*S Afr Med J* 1970;44:649-652.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

4. The Pregnant Teenager - An Interracial Study.  
M. Notelovitz.  
*S Afr Med J* 1970;44:55.
5. Transplacental Haemorrhage and the Mode of Placental Delivery.  
M. Notelovitz, D. Dalrymple, B. Grobelaar, and M. Gibson.  
*S Afr Med J Obstet Gynaecol* 1971;9:51-54.
6. Transplacental Haemorrhage Following Caesarean Section.  
M. Notelovitz, D. Dalrymple, B. Grobelaar, and M. Gibson.  
*S Afr Med J* 1972;46:128.

**Gynecological/Surgical Practice**

1. Bilharzia of the Female Genital Tract.  
M. Notelovitz and T.P. Boule.  
*S Afr Med J Obstet Gynaecol* 1964;38:48-51.
2. Wound Healing and Wound Disruption.  
M. Notelovitz.  
*S Afr Med J* 1967;41:323-327.
3. Tolerance of Elderly Patients to Major Gynaecological Surgery.  
M. Notelovitz.  
*S Afr Med J* 1972;46:1618-1621.
4. Beware the Weeping Womb.  
M. Notelovitz.  
*S Afr Med J* 1973;47:1653-1655.

**Original Clinical Observations**

1. Silent Abruption of the Posteriorly Inserted Placenta.  
M. Notelovitz.  
*S Afr Med J* 1974;48:93-95.
2. Painless Abruptio Placentae.  
M. Notelovitz, S.F. Bottoms, D.F. Dase, and P.J. Leichter.  
*Obstet Gynecol* 1979;53:270-272.

**Hypotheses**

1. Oestrogen, Fatty Acids, and the Pregnant Diabetic - A Hypothesis.  
M. Notelovitz.  
*S Afr Med J Obstet Gynaecol* 1967;4:9-12, 1967.
2. Oestrogens and the Respiratory Distress Syndrome. (Letter).  
M. Notelovitz.  
*Lancet* 1974;;505-506.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

3. Estrogens, Lipids, and Heart Disease. (Non-Review).  
M. Notelovitz.  
*The Female Patient* 1980;5:18.

**Diabetes and Pregnancy**

1. Tolbutamide and Chlorpropamide During Pregnancy in Human Diabetics.  
W.P.U. Jackson, G.D. Campbell, M. Notelovitz, and D. Blumson.  
*Diabetes* 11 1962; (Suppl) 98-103.
2. The Pregnant Diabetic - Facts and Fancies.  
M. Notelovitz.  
*S Afr Med J* 1968;42:895-898.
3. The Adrenal Cortex and the Pregnant Diabetic.  
M. Notelovitz.  
*S Afr Med J* 1969;42:975-978.
4. Carbohydrate Tolerance in the Pregnant Natal Indian.  
M. Notelovitz.  
*S Afr Med J* 1969;43:367-371.
5. Complications of Diabetes in Pregnancy.  
M. Notelovitz.  
*Livingstone Hospital Proceedings* 1969; 3:95.
6. Diabetes Mellitus Today: A Brief Review of Present-Day Concepts Regarding  
Its Aetiology.  
M. Notelovitz.  
*Med Proc* 1969;14:150.
7. Genetics and the Natal Indian Diabetic.  
M. Notelovitz.  
*S Afr Med J* 1969;42:1245.
8. Intravenous Glucose Tolerance in Late Pregnancy.  
M. Notelovitz.  
*S Afr Med J* 1969;42:1016-1018.
9. Management of the Pregnant Diabetic.  
M. Notelovitz.  
*Livingstone Hospital Proceedings* 1969;3:95.
10. The Obstetrician and the Foetus of the Diabetic Mother.  
M. Notelovitz.  
*S Afr Med J* 1969;43:143-146
11. Prediabetes in Pregnancy.  
M. Notelovitz.  
*Livingstone Hospital Proceedings* 1969 3:31.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

12. The Pregnant Natal Indian Diabetic.  
M. Notelovitz.  
*S Afr Med J* 1969;43:395-399.
13. Carbohydrate tolerance in the non-pregnant Natal Indian female.  
Notelovitz M.  
*S Afr Med J*. 1969 Mar 8;43(10):259-66. No abstract available.
14. The Pregnant Bantu Diabetic.  
M. Notelovitz.  
*S Afr Med J* 1970;44:1171-1175.
15. Sulphonylurea Therapy in the Treatment of the Pregnant Diabetic.  
M. Notelovitz.  
*S Afr Med J* 1971;45:226-229.
16. Capillary Permeability in Pregnant Diabetics and Nondiabetics.  
M. Notelovitz.  
*S Afr Med J* 1972;45:491-493.
17. Gestational Diabetes in General Practice.  
M. Notelovitz.  
*S Afr Med J* 1974;48:417-420.
18. Milestones in the History of Diabetes: A Brief Survey.  
M. Notelovitz.  
*S Afr J Obstet Gynaecol* 1974;44:1158.
19. Protein Calorie Malnutrition, Gastric Motility, and Diabetes. (Letter).  
M. Notelovitz.  
*S Afr Med J* 1974;48:940.
20. Treatment of Pregnant Diabetics with Oral Hypoglycemic Drugs. (Letter).  
M. Notelovitz.  
*Lancet* 1974; 2:902.
21. The Effect of Long-Term Oestrogen Replacement Therapy on Glucose and Lipid Metabolism in Post-Menopausal Women.  
M. Notelovitz.  
*S Afr Med J* 1976;50:2001-2003.
22. Growth Hormone Secretion in Insulin-Dependent Pregnant Diabetics.  
M. Notelovitz and S. James.  
*Obstet Gynecol* 1976; 47:449-453.
23. Human Placental Lactogen in Pregnant Natal Indian Diabetics.  
M. Notelovitz and S. James.  
*S Afr Med J* 1976;50:473-476.
24. Insulin Secretion in Healthy Pregnant Natal Indians.  
M. Notelovitz.  
*S Afr Med J* 1976;50:693-696.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

25. Insulin Secretion in Pregnant Diabetic Indian Women in Natal.  
M. Notelovitz.  
*S Afr Med J* 1976;50:688-692.
26. An Interracial Comparison of Insulin Secretion in Normal Nonpregnant Women.  
M. Notelovitz and S. James.  
*S Afr Med J* 1976;50:1214-1217.
27. Plasma Insulin Response Following Oral and Intravenous Glucose in Pregnant Diabetic Women.  
M. Notelovitz and S. James.  
*Obstet Gynecol* 1976;48:268-273.
28. Plasma Free Fatty Acids in Pregnant Insulin-Dependent Natal Indian Diabetics.  
M. Notelovitz and S. James.  
*Horm Metab Res* 1977;9:105-108.
29. Tolbutamide-Induced Insulin Release in Pregnant Diabetics.  
M. Notelovitz and S. James.  
*Horm Metab Res* 1977;9:167-252.

**Basic Research/Animal Research/Physiology**

1. New Technique for Uterine Metabolism Studies.  
R.M. Abrams and M. Notelovitz.  
*Gynecol Invest* 1976;7:13.
2. Vaginal Blood Flow Response to Immersion of Hand in Ice Water.  
R.M. Abrams, C.J. Wilcox, and M. Notelovitz.  
*Physiologist* 1976;19:103.
3. Cold Pressor Test In Women: Effect on Vaginal Blood Flow.  
R.M. Abrams, M. Notelovitz, C.J. Wilcox, B. Cantor, and J.L. Dockery.  
*Am J Obstet Gynecol* 1977;127:525-528.
4. Heat Production of Fetal Sheep Brain in Utero.  
R.M. Abrams, J.F. Clapp, M. Notelovitz, T. Tyler, and S. Cassin.  
*J Appl Physiol* 1977;43:747-749.
5. In Vivo Measurement of Regional Cerebral Metabolic Rate in Fetal Sheep in Utero.  
R.M. Abrams, J. Clapp, and M. Notelovitz.  
*Gynecol Invest* 1977;8:35.
6. Cerebral Metabolic Rate of the Fetal Sheep.  
R.M. Abrams, M. Notelovitz, and S. Cassin.  
*Eur J Obstet Gynecol Reprod Biol* 1978; 8:329-334.
7. Distribution of Estrogen and Progesterone Receptors, and Peroxidase in Human Endometrium.  
J.C.M. Tsibris, C.R. Cazenave, B. Cantor, M. Notelovitz, P. Kalra, and W.M. Spellacy.  
*Am J Obstet Gynecol* 1978;132:449-454.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

8. Effect of Diazepam on Serum Testosterone and the Ventral Prostate Gland in Male Rats.  
P.S. Cook, M. Notelovitz, P.S. Kalra, and S.P. Kalra.  
*Arch Androl* 1979;3:31-35.
9. Effect of Ethyl Alcohol on Maternal and Fetal Acid-Base Balance and Cardiovascular Status in Chronic Sheep Preparation.  
P.S. Cook, R.M. Abrams, M. Notelovitz, and J.E. Frisinger.  
*Br J Obstet Gynaecol* 1981; 88:188-194.
10. The Uneven Distribution of Estrogen and Progesterone Receptors in Human Endometrium.  
J.C.M. Tsbiris, F.L. Fort, C.R. Cazenave, B. Cantor, W.A. Bardawil, M. Notelovitz and W.N. Spellacy.  
*J Steroid Biochem* 1981;14(11).
11. Mestranol-Induced Hypertension: Characterization of Cytochrome P-450 Dependent Catechol Estrogen Formation in Brain Microsomes.  
K.T. Shiverick and M. Notelovitz.  
*Biochem Pharmacol* 1983;32(1):101-106.
12. Regulation of Cytochrome P-450 Dependent Catechol Estrogen Formation in Rat Liver Microsomes: Evidence for Involvement of Estrogen Receptors.  
K.T. Shiverick and M. Notelovitz.  
*Biochem Pharmacol* 1983;32:2399-2403.
12. Effect of ethyl alcohol infusions on glucose and hormone status in ovine pregnancy.  
Cook PS,Head HH,Notelovitz M,Abrams RM.  
*Int J Gynaecol Obstet* 1984 June;22(3):237-42.

**Miscellaneous**

1. Hormone Replacement: Gynecologists Consider the Heart of the Matter.  
M. Notelovitz and L. Nachtigall.  
*JAMA* 258(12):1573-1577.
2. Foreword. In: *The Menopause: Comprehensive Management*, 2nd Edition.  
M. Notelovitz.  
Edited by Bernard A. Eskin, M.D.
3. Female Sexuality: Keeping Menopausal Women Healthy. (An Interview.)  
M. Notelovitz, interviewed by A.P. Lewis.  
*Medical Aspects of Human Sexuality* September, 1986, 70-76.
4. Osteoporosis and the Gynecologist.  
M. Notelovitz.  
In "Osteoporosis: Current Concepts - Report of the 7th Ross Conference on Medical Research."  
Ross Laboratories, Columbus, Ohio, 1987.
5. Exercise and Osteoporosis.  
M. Notelovitz.  
*Your Patient & Fitness In Obstetrics and Gynecology*, Volume 1, Number 4, 10-16,  
September/October, 1987.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

6. Oral Contraceptive Use Past the Age of 35.  
M. Notelovitz.  
In "The Importance of Hormone Balance to Metabolic Effects on the Female Physiology."  
*Gynecol Obstet Invest*  
Hawaii Symposium, November 22, 1987, pp 6-7. Karger.
7. Noncontraceptive Hormone Therapy and Breast Cancer: A Personal Perspective of Clinical Guidelines.  
M. Notelovitz.  
*Menopause Management* II(3), December, 1989.
8. Management of the Changing Vagina.  
M. Notelovitz.  
*J Clin Practice in Sexuality*, Special Issue, 1990.
9. Geriatric Gynecology. (ACOG/AMA/CME.)  
H.R.K. Barber, J.L. Breen, G.W. Morley and M. Notelovitz.  
*The Female Patient* 1990;15(3):37-49, March.
10. Osteoporosis: A Preventable Condition.  
M. Notelovitz.  
*Medical Digest* 1991;11(1):2-5, Winter/Spring.
11. A Team Approach to Menopausal Health Care: Its Time Has Come.  
M. Notelovitz.  
*Menopause Management* II(2):26-30, February, 1993.
12. Foreword.  
M. Notelovitz.  
In: *Is It Hot in Here or Is It Me?* by Gayle Sand.  
HarperCollins, New York, 1993.
13. Proceedings of the First International Workshop on Estring.  
Edited by M. Notelovitz.  
Royal Society of Medicine Services Limited, London, 1993.
14. Hormone Replacement Therapy and Compliance.  
M. Notelovitz  
*Menopausal Medicine*, July 1993;1(3):4-6.
15. Oral Contraceptives and Coagulation Problems.  
V.M. Wilt, J.G. Gums and M. Notelovitz.  
*Fertility Control Reviews*, Medicom Europe, The Netherlands 1994; 3(1):3-10.
16. Postmenopausal Production of Endogenous Hormones and their Relevance to Clinical Practice.  
Notelovitz M. *Menopause Update* 2005;8:2-4.(October 2005)
17. Rational Hormone Management of the Menopause.  
Notelovitz M. *Gynecology Forum* 2004;9:23-28.

**ARTICLES TRANSLATED INTO FOREIGN LANGUAGES**

1. The Role of the Gynecologist in Osteoporosis Management. Translated into Japanese: Proceedings of the Gynecologists' Meeting on Osteoporosis, Japan, January, 1990.
2. Estrogenos en Mujeres Postmenopausicas. Una Opinion Contraria.  
M. Notelovitz.  
*Medicina Familiar* September 1990;2(3):176-180, Maracaibo, Venezuela.
3. La salud cardiovascular en las mujeres postmenopausicas. Acta Ginecologica, XLVIII(8):329-346, October, 1991.

**AUDIO-VISUAL/EDUCATIONAL MATERIALS**

1. Calcium and Osteoporosis  
Morris Notelovitz, M.D., Ph.D.  
The National Dairy Board, 1985.
2. Menopause: Changes for the Better  
Morris Notelovitz, M.D., Ph.D.  
Lifetime Medical Television, 1985.
3. Osteoporosis  
Morris Notelovitz, M.D., Ph.D.  
Milner-Fenwick, September 1985.
4. The Climacteric Years  
Morris Notelovitz, M.D., Ph.D.  
Milner-Fenwick, June 1986.
5. Hormone Therapy  
Morris Notelovitz, M.D., Ph.D.  
Milner-Fenwick, May 1987.
6. Management of the Climacteric  
Morris Notelovitz, M.D., Ph.D.  
Audiodigest Foundation, Vol. 34, #21, November 3, 1987.
7. Cardiovascular Effects of Hormone Replacement Therapy  
Morris Notelovitz, M.D., Ph.D.  
Emory Medical School, Elizabeth Connel Ed., 1988.
8. Transdermal Estrogen - Pros and Cons  
Morris Notelovitz, M.D., Ph.D., R. Gambrell, M.D., L. Nachtigall, M.D.,  
Discussants.  
Continuing Medical Education Program presented by ACOG.  
*ACOG Update* 1989; Volume 14: #11: pp 1-9.
9. Osteoporosis: The Silent Disease  
WUFT 1996

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

10. 1-800-MENO-ASK Hotline  
Morris Notelovitz, M.D., Ph.D.  
Toll-free member call-in service provided by The National Menopause Foundation, Inc. supplying pre-recorded information on various women's health related topics.
11. *The Women's Health Digest*  
Morris Notelovitz, M.D., Ph.D., Publisher  
A quarterly consumer medical journal for women offering articles on and insights into health issues for women in midlife with the substance and detail of a medical journal put into lay language.
12. Osteoporosis  
CD Rom
13. Androgens and Bone  
CD Rom

**FUNDED RESEARCH SUPPORT**

1. Pfizer Laboratories, 1963-1968.
2. Council for Scientific and Industrial Research, 1969-71.
3. Ayerst Laboratories, 1970-1972.
4. Medical Research Council (RSA), 1971-1973.
5. National Institutes of Health (USA), 1976-1977.
6. Alza Laboratories (USA), 1977.
7. Ayerst Laboratories, 1977-1978.
8. Mead Johnson Laboratories (USA), 1977-1978.
9. Ortho Pharmaceuticals (USA), 1978-1979.
10. Mead Johnson Laboratories (USA), 1979.
11. National Institutes of Aging: Biological and Psychosocial Aspects of Aging (Over 3 years), 1979-82.
12. Schering Laboratories, 1980-1981.
13. Mead Johnson Laboratories, 1981.
14. Schering Laboratories, 1981-1982.
15. Upjohn Laboratories, 1981-1983.
16. Nautilus, Inc., 1982-1990.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

17. Ayerst Laboratories, 1982.
18. FL Dept. of Health & Rehabilitative Services I, 1983.
19. FL Dept. of Health & Rehabilitative Services II, 1983-84.
20. Bruner Foundation, 1983-1985.
21. Schering Laboratories, 1983-1984.
22. Ciba-Geigy, 1983-1984.
23. Ayerst Laboratories, 1985.
24. Wyeth Laboratories, 1985-1986.
25. Nuclear Data, 1985-1986.
26. Lederle Laboratories, 1986.
27. Florida Department of Health & Rehabilitative Services III, 1986.
28. Abbott Laboratories, 1986.
29. Ayerst Laboratories, 1987.
30. NIH (Co-Investigator with Dan Martin, Ph.D.) Walking and Bone Mass, 1988-1989.
31. Ayerst Estrogen, Exercise and Lipid Study, 1988-1990.
32. Reid-Rowell Estratab and Estratest and Effects on Lipids and Bone Mass, 1988-1990.
33. Bartor Estrapel and Effects on Estradiol Production Levels, 1989.
34. Columbia Laboratories, Inc. Vaginal Moisturizing Gel Study, 1989.
35. Organon, Inc. Desogestrel O.C. CTR-04 Study, 1990.
36. Health & Sciences Research, Inc. Noven Patch Study, 1990.
37. 3M/Bio-Pharm. Estradiol Patch Study, 1990.
38. Wyeth-Ayerst Laboratories: Trigonitis, 1992.
39. Miles, Inc.: Clotrimazole 2% Vaginal Cream, 1993.
40. Mead Johnson Laboratories: Evaluation of the effect of 0.5 mg Estrace Compared to Placebo on Biochemical Markers of Bone Resorption in Postmenopausal Women, 1994.
41. Kabi Pharmacia: Comparison of a continuous low dose of estradiol released from a vaginal ring versus conjugated equine estrogen in a vaginal cream in the treatment of postmenopausal women with signs and symptoms of urogenital atrophy, 1992.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

42. Zeneca Pharmaceuticals Group: Comparison of 3.6 mg ZOLADEX therapy with or without hormone replacement therapy for the treatment of endometriosis, 1992.
43. Novo Nordisk Pharmaceuticals, Inc.: Evaluation of Estrofem® 0.25, 0.5, 1.0, and 2.0 mg on relief of vasomotor and other symptoms of the menopause, 1993.
44. Solvay Pharmaceuticals, Inc.: Investigation of Three Doses of Esterified Estrogens (Estratab®) on Bone Mineral Density and Parameters of Bone Metabolism in Postmenopausal Women, 1992.
45. Solvay Pharmaceuticals, Inc.: Study on the Effects of Estratest H.S.®, Estratest® and Premarin® in Surgically Menopausal Women, 1992.
46. Solvay Pharmaceuticals, Inc.: Study of Esterified Estrogens Plus Methyltestosterone (Estratest®) and Esterified Estrogens (Estratab® 1.25 mg) in Surgically Postmenopausal Women: Symptoms, Psychometric Assessments, Serum and Saliva Hormone Levels, 1993.
47. ClinTrials Research, Inc./ TheraTech, Inc.: Comparison of Two Doses of an Estradiol Matrix Transdermal Delivery System (EMTDS) with a Placebo Matrix Transdermal Delivery System in the Treatment of Women with Postmenopausal Symptoms, 1994.
48. Novo Nordisk Pharmaceuticals, Inc. (Protocol VAG/PD/9/USA)  
"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Multicenter Study Comparing the Efficacy and Safety of Vagifem 10 □g and 25 □g doses in treatment of estrogen deficiency derived atrophic vaginitis."
49. Organon Inc./Pharmaco LSR (Protocol 086-001)  
"An Open Label, Multicenter, Non-Comparative Safety and Efficacy Study of the Desogestrel Containing Oral Contraceptive CTR 25."
50. Organon Inc./Pharmaco LSR(Protocol 092-001)  
"An Open-Label, Randomized, Parallel, Comparative, Multicenter, Safety and Efficacy Study of Triphasic Combination Oral Contraceptives, CTR 99 and CTR 77, versus Ortho-Novum 7/7/7."
51. Ostex International, Inc. (Protocol OST-C2)  
"A Study of the Use of Osteomark in the Quantitation of cross-linked N-telopeptides of type I collagen as an aid in Monitoring the Effect of Therapies used for the Prevention and Management of Bone Loss in Postmenopausal Women."
52. ClinTrials Research, Inc./TheraTech, Inc. (Protocol E94001A)  
"An Open-Label, Multicenter **Extension of Protocol No. E94001** to Describe the Use of Two Doses of an Estradiol Matrix Transdermal Delivery System (EMTDS) in the Treatment of Women with Postmenopausal Symptoms."
53. Novo Nordisk Pharmaceuticals, Inc. (Protocol KLIM/PD/7/USA)  
"A Double-Blind, Randomized, Parallel Group, Multicenter, Dose Finding Study Comparing the Efficacy and Safety of 1 mg 17β-estradiol in combination with low doses of norethindrone acetate with that of 1 mg 17β-estradiol alone on the endometrium in postmenopausal women."
54. Procter & Gamble Pharmaceuticals/G.H. Besselaar Associates (Protocol RPE 002494)  
"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of Risedronate (NE-58095) plus Estrogen versus Estrogen only in the Prevention of Bone Loss in Postmenopausal Women."

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

55. Sterling Winthrop Pharmaceuticals (Protocol SR 41319B-004)  
"A Phase III Study of Intermittent Cyclical Tiludronate in the Treatment of Post-menopausal Women with Low Bone Mineral Mass and No Vertebral Fractures."
56. Organon Inc./Quintiles Inc. (Protocol 069-001)  
"An Open-Label Noncomparative Efficacy and Safety Study of Implanon, A One-Rod Contraceptive Implant Containing 3-Ketodesogestrel in Healthy Female Volunteers, With Subsets For Pharmacokinetic Measurements, Ophthalmological Assessments, Carbohydrate Metabolism, Lipid Metabolism and Endometrial Morphology."
57. Rhône-Poulenc Rorer (Protocol RPR 106522-303)  
"A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Menopausal Symptom Study of Three Doses of RPR Estradiol/Norethisterone Acetate (NETA) Patches in a Sequential Wear Hormone Replacement Therapy (HRT) Regimen."
58. Bayer Corporation (Protocol S95-003)  
"A Multi-Center, Prospective, Randomized, Single-Blind, Parallel-Group Comparison of the Clotrimazole 1-Day (One 500 mg Vaginal Insert) and the Clotrimazole 3-Day Regimens (One 200 mg Vaginal Insert Daily for 3 Days) with the Clotrimazole 7-Day Regimen (One 100 mg Vaginal Insert Daily for 7 Days) for the Treatment of Vulvovaginal Candidiasis."
59. Eli Lilly & Company (Protocol H3S-MC-SAAL)  
"Duloxetine Versus Oxybutynin in Patients with Urge Urinary Incontinence: A Multiple-Dose Study for Efficacy and Safety"
60. Eli Lilly & Company (Protocol H35-MC-GGK)  
"Comparison of Raloxifene HCl and Placebo in the Treatment of Postmenopausal Women with Osteoporosis."
61. Procter & Gamble Pharmaceuticals/G.H. Besselaar Associates (Protocol RVN 008993)  
"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Determine the Efficacy and Safety of Risedronate (NE-58095) in the Treatment of Postmenopausal Women with Established Osteoporosis-Related Vertebral Deformities."
62. Procter & Gamble Pharmaceuticals/Quintiles Inc. (Protocol RHN 009193)  
"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Risedronate in the Treatment of Osteoporosis in Elderly Women."
63. Sterling Winthrop Pharmaceuticals (Protocol SR 41319B-004)  
"A Phase III Study of Intermittent Cyclical Tiludronate in the Treatment of Established Post-Menopausal Osteoporosis."
64. Organon Inc. (Protocol 010-006)  
"A Dose-Finding Efficacy & Safety Study of Tibolone (Org OD 14) for Prevention of Osteoporosis in Postmenopausal Women."
65. The Upjohn Company (Protocol M5410/0336)  
"Evaluation of Endometrial Histology and Bone Mineral Density (BMD) in Post- Menopausal Women Receiving OGEN/PROVERA) Hormone Replacement Therapy (HRT)."

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

66. Boehringer Mannheim Pharmaceuticals Corporation (Protocol MF 4380)  
"Double-blind Placebo-controlled, Randomized, Multicenter Study on the Efficacy and Safety of Ibandronate (BM 21.0955) during Three Years Treatment in Patients with Postmenopausal Osteoporosis using an Intermittent (every 3 months) i.v. Injection Regimen of 1 mg."
67. Eli Lilly & Company (Protocols H3S-MC-GGHD)  
"Comparison of Raloxifene HCl, Continuous Combined Hormone Replacement Therapy, and Placebo in Early Postmenopausal Women: Effects on Bone, Endometrium, Menopausal Symptoms, and Lipids."
68. Eli Lilly & Company (Protocol H3S-MC-GGHD)  
"Comparison of Raloxifene HCl, Estrogen and Placebo on the Uterus in Healthy Postmenopausal Women."
69. R.W. Johnson PRI (Protocol STNRG-CHRT-102)  
"A Multicenter, Randomized, Double-Blind, Parallel Group, Dose-Ranging Study to Evaluate the Safety of a CYCLOPHASIC Hormone Replacement Therapy Regimen of Estradiol and Norgestimate and its Effect on Endometrial Histology, Vaginal Bleeding and Metabolic Parameters in Postmenopausal Women."
70. Bristol-Myers Squibb (Protocol CV141-001)  
"Efficacy and Safety Comparison of Estrogel® and Placebo in the Treatment of Menopausal Women with Vasomotor Symptoms"
71. R.W. Johnson (Protocol ESTNRG-CHRT-104)  
"A Multicenter, Double-Blind, Randomized Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral 17 $\beta$ -Estradiol for the Treatment of Vasomotor Symptoms and Genital Atrophy in Postmenopausal Women"
72. Eli Lilly & Company (Protocol H3S-MC-GGHF)  
"Raloxifene HCL Versus Placebo Versus Hormone Replacement Therapy: Histomorphologic Effects in Bone in Healthy, Postmenopausal Women".
73. Novo Nordisk (Protocol LEV/PD/17/USA)  
"A Double-Blind, Placebo Controlled Trial to Study the Safety and Efficacy of 2.5, 10 and 40 mg of Levormeloxifene for the Prevention of Postmenopausal Bone Loss."
74. Pfizer (Protocol 174-106)  
"A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Droloxifene 40 mg/d, and 80 mg/d on BMD in Osteopenic, Postmenopausal Women."
75. Procter & Gamble (Protocol 1996023)  
"A Randomized, Double-Blind, Placebo-Controlled, 24 Month, Dose-Ranging, Multi-Center Study Protocol Comparing EMTDS to Placebo in the Prevention of Bone Loss in Hysterectomized Postmenopausal Women."
76. Procter & Gamble (Protocol 1996022)  
"A Randomized, Parallel Group, Double-Blind, 12 Month, Dose-Ranging, Multi-Center Study Protocol To Determine the Lowest Effective Continuous and Sequential Transdermal NETA Dose Required To Prevent Estrogen-Induced Endometrial Hyperplasia."

**STUDENT AND GRADUATE RESEARCH**

Conceptual stimulus, guidance, and financial support were obtained for the following student research projects:

1. Phil Cook "Alcohol in Pregnancy."  
Financial Support: Alza Laboratories.  
Student South Atlantic Association for Obstetrics and Gynecology Fellowships.  
(The Results of this research were presented at the 1979 Society for Gynecologic Investigation in San Diego.)
2. Holly Jones: "Vaginal Blood Flow and Estrogen Therapy"  
Financial Support: Ayerst Laboratories.  
Student South Atlantic Association of Obstetrics and Gynecology Fellowships.  
Published Am J Obstet Gynecol 143:375, 1982.
3. I.C. Song: "Effects of Anti-Histamines and Steroids on the Hypothalamic and Pituitary Concentrations of Methionine-Enkephalin in Ovariectomized Rats."  
Thesis for Degree of Master of Science, Graduate Council of the University of Florida.
4. Rogene Tesar: "Mast Cell Activity in Bone and Vaginal Tissue in Calcium and Vitamin Deficient Rats."  
Research Thesis for Ph.D. Requirement.
5. Kim Caramelli: "Effect of Loadbearing During Treadmill Walking in Women 57 to 67 Years."  
Research Thesis for M.A. in Physical Education.
6. Kathryn S. Bland-Stallings: "Effects of Nautilus and Calisthenics on Muscular Strength, Muscular Endurance and Flexibility for Postpartal Women."  
Research Thesis for M.A. Requirement.
7. Leah J. Roen: "Osteoporosis: A Geographic Explanation."  
Research Thesis for M.A. Requirement.
8. Richard M. Speer: "The Radiation Aspects of Bone Densitometry Measurement." Research Thesis for M.S. Requirement.

**PARTICIPATION IN INTERNATIONAL MEETINGS**

1. International Congress on Diabetes, Stockholm, Sweden, 1967.
2. Sixth World Congress on Fertility-Sterility, Tel Aviv, Israel, 1968.
3. Rhodesian International Medical Congress, Bulawayo, Rhodesia, 1968.
4. International Congress of Clinical Chemistry, Geneva, Switzerland, 1969.
5. International Congress of Obstetricians and Gynecologists, New York, N.Y., U.S.A., 1970.
6. International Congress on Fertility and Sterility, Tokyo, Japan, 1971.
7. British Congress of Obstetricians and Gynecologists, London, United Kingdom, 1974.
8. First International Congress on the Menopause, Montpellier, France, 1976.
9. Second International Congress on the Menopause, Jerusalem, Israel, 1978.
10. Ninth World Congress of Obstetrics and Gynecology, Tokyo, Japan, 1979.
11. Third International Congress on the Menopause, Ostend, Belgium, 1981.
12. Tenth World Congress of Obstetrics and Gynecology, San Francisco, California, U.S.A., 1982.
13. Fourth International Congress on the Menopause, Orlando, Florida, U.S.A., 1984.
14. International Osteoporosis Congress, Copenhagen, Denmark, 1984.
15. International Menopause Seminar, Stockholm, Sweden, 1985.
16. International Menopause Symposium, Berlin, Germany, 1985.
17. Eleventh World Congress of Obstetrics and Gynecology, Berlin, Germany, 1985.
18. Second International Congress on Osteoporosis, Aalborg, Denmark, Sweden, 1987.
19. Second International Symposium on Premenstrual, Postpartum and Menopausal Mood Disorders. Kiawah Island, South Carolina, U.S.A., 1987.
20. Fourth National Congress on the Menopause. Perth, Australia, 1987.
21. Fourth Australian Congress on Obstetrics and Gynecology, Perth, Australia, 1987.
22. International Conference on Progestogens, Naples, Florida, U.S.A., 1988.
23. Asian-Pacific Osteoporosis Conference, Honolulu, Hawaii, 1989.
24. First Congress on Osteoporosis - Japan Gynecological Society, Tokyo, Japan, 1990.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

25. Royal College of OBG Scientific Advisory Meeting on Osteoporosis, London, United Kingdom, 1990.
26. Congress on Climacteric Medicine: Buenos Aires, Argentina, 1990.
27. Cursos de Verano de la Universidad Complutense on "Edad Critica: Climaterio y Menopausia," Madrid, Spain, July, 1990.
28. Argentine Congress on Obstetrics and Gynecology, and The Menopause Symposium, Buenos Aires, Argentina, September, 1990.
29. Third International Symposium on Osteoporosis, Copenhagen, Denmark, October, 1990.
30. Sixth International Congress on the Menopause, Bangkok, Thailand, October, 1990.
31. Novo Nordisk Symposium: Cardiovascular Effects of HRT "Modifying Influence of Lifestyle on Metabolic effects of Hormone Replacement Therapy" Copenhagen, Denmark, February, 1991.
32. International Expert Meeting on Contraception & Gonadotrophin Therapy. Munich, Germany, June, 1991.
33. Thirteenth World Conference of Gynecology and Obstetrics (FIGO), Singapore, September, 1991.
34. Second Annual Meeting of the North American Menopause Society, Montreal, Canada, September, 1991.
35. First Congress of the Scandinavian Menopause Society, Copenhagen, Denmark, April, 1992.
36. Columbia Laboratories, Inc. Symposium on Replens®, Paris, France, June, 1992.
37. First International Workshop on Estring, Paris, France, March 1, 1993.
38. Seventh International Congress on the Menopause, Stockholm, Sweden, June 20-24, 1993.
39. Annual Meeting of the Swedish Society of Obstetrics and Gynecology, Västerås, Sweden, September 8-9, 1993.
40. International Consensus Conference on Hormone Replacement Therapy and the Cardiovascular System, Bethesda, Maryland, December 2-4, 1993.
41. 37th Annual Meeting of the Pan American Conference on Fertility, Sterility and Menopause, Las Croabas, Puerto Rico, February 6-13, 1994.
42. Third International Symposium - Osteoporosis: Research Advances and Clinical Applications, Washington, DC, March 2-5, 1994.
43. Novo Nordisk Fifth International Symposium, Copenhagen, Denmark, May 6-7, 1994.
44. Fourteenth World Congress of Gynecology and Obstetrics (FIGO), Montreal, Canada, September 24-30, 1994.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

45. Fifth National Congress of Gynecology and Obstetrics and Sixth Meeting of the Regional Group of Mexico-Caribe FLASOG, Merida, Mexico, November 6-10, 1994.
46. HRT and Cardiovascular Diseases: State of the Art, Paris, France, October 6, 1995.
47. The Sixth Gynecology Osteoporosis Society Meeting, Fukuoka City, Japan, November 10, 1995.
48. Novo Nordisk Women's Healthcare Symposium, Barcelona, Spain, September 13-14, 1996.
49. N.V. Organon, Expert Meeting Estradiol Implants, Madrid, Spain, October 16-18, 1996.
50. 33rd Annual Andre Aisenstadt Clinical Day: "Contemporary Perspectives in Women's Health in the Menopause: Can We Do Better?" ; Montreal, Canada, October 30, 1996.
51. Fifteenth World Congress of Gynecology & Obstetrics (FIGO). Copenhagen, August 4-6, 1997.
52. Visiting Professor Lecturer: RSA (January 20-31, 1997 tour)
53. Symposium on Cardiovascular Disease. Cancun, February 4-5, 1997.
54. Menopause Management. Quebec, March 21-23, 1997.
55. World Wide HRT Thought Leaders Advisory Board. Paris, June 20-21, 1997.
56. Visiting professor Lecturer: Istanbul, Ankara, Ismir (Turkey), October 21-26, 1997.
57. Visiting Professor Lecturer: Korean Menopause Society, November 2nd, 1997.
58. Lecturer. Philippine Menopause Society. Manila, April 30<sup>th</sup>, 1998
59. Lecture Series: Beijing, Shanghai, Guangzhou, May 4<sup>th</sup>, 6<sup>th</sup> and 8<sup>th</sup>, 1998.
60. International Symposium on New Trends in Menopausal Care. March 15<sup>th</sup>, Jerusalem, Israel.
61. Recent Advances in Menopause. Sede, Turkey. May 21<sup>st</sup>- 24<sup>th</sup>, 1998.
62. International Advisory Board. Merk. Florence, Italy. June 12<sup>th</sup>, 1998.
63. Women's Health and Menopause: Risk Reduction Strategies. June 13<sup>th</sup> - 16<sup>th</sup> Florence, Italy. 1998.
64. Hormone Therapy Training Program. Novo-Nordisk. Copenhagen. August 24<sup>th</sup> - 26<sup>th</sup> 1998.
65. NAMS Meeting. Toronto, Canada. September 16<sup>th</sup> - 19<sup>th</sup> 1998.
66. New Trends in HRT Management. Rome, Italy. October 9<sup>th</sup> - 11<sup>th</sup> 1998.
67. Second Latin American Congress on the Climacteric and Menopause. Sao Paulo, Brazil. October 25<sup>th</sup> - 28<sup>th</sup> 1998.
68. Mexican National Obstetrics and Gynecology Congress. October 25<sup>th</sup> - 30<sup>th</sup> 1998.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

69. Visiting Lecturer: Istanbul, Izmir and Ankara, Turkey. March 6<sup>th</sup> - 16<sup>th</sup> 1999.
70. New Perspectives in Contraception and Hormone Therapy. Berlin. April 23<sup>rd</sup> 1999.
71. Visiting Professor/Lecturer. Johannesburg, Pretoria, Durban, RSA. April 28<sup>th</sup>, 29<sup>th</sup> 1999.
72. Tenth World Congress on Human Reproduction. Salvador, Brazil. May 4<sup>th</sup> - 8<sup>th</sup> 1999.
73. New Trends in HRT Management. Prague, Czech Republic. May 28<sup>th</sup> - 29<sup>th</sup> 1999.
74. Visiting Professor/Lecturer. Jerusalem, Haifa, Tel Aviv. May 30<sup>th</sup> - June 2<sup>nd</sup> 1999.
75. Pan Arab Gynecologic Conference. Beirut, Lebanon. June 3<sup>rd</sup> - 6<sup>th</sup> 1999.
76. HRT Advisory Board Meeting. Novo Nordisk. Copenhagen, Denmark. June 8<sup>th</sup> 1999.
77. HRT Training Workshop for Belgium Physicians. Novo Nordisk. Copenhagen. June 10<sup>th</sup> and 11<sup>th</sup> 1999.
78. Visiting Professor/Lecturer. Hong Kong Obstetric and Gynecologic Society. Hong Kong. July 29<sup>th</sup> 1999.
79. 1999 Oxford Symposium on the Menopause. Oxford UK. September 2<sup>nd</sup> - 3<sup>rd</sup> 1999.
80. Challenging Cases in Menopause. AJRM 32<sup>nd</sup> Annual Meeting. September 25<sup>th</sup> - 30<sup>th</sup> 1999.
81. International Menopause Society, World Congress. Yokohama, Japan. October 17<sup>th</sup> - 21<sup>st</sup> 1999.
82. Visiting Professor/Lecturer. Singapore Obstretical and Gynecological Society. Singapore. October 25<sup>th</sup> 1999.
83. Royal Thai College of Obstetrics and Gynecology 14<sup>th</sup> Annual Scientific Meeting. Bangkok, Thailand. October 26<sup>th</sup> - 29<sup>th</sup> 1999.
84. Visiting Professor/Lecturer. Brisbane and Melbourne, Australia. October 29<sup>th</sup> - November 4<sup>th</sup> 1999.
85. New Trends in HRT Management. Facade, Thailand. November 5<sup>th</sup> - 6<sup>th</sup> 1999.
86. Philippine Obstetric and Gynecologic Society 53<sup>rd</sup> Annual Meeting. Manila, Philippines. November 16<sup>th</sup> - 19<sup>th</sup> 1999.
87. Novo Nordisk. Activelle Launch Satellite Symposia. Portugal. January 24–25, 2000.
88. Symposium on the Menopause: Recent Progress in HRT, Osteoporosis and Cardiovascular Disease. Keelung, Taiwan, ROC. April 8<sup>th</sup> 2000.
89. VI National Congress of the Spanish Association of Menopause. Barcelona. May 9–12, 2000.
90. Fifth European Congress on Menopause. Copenhagen, Denmark. July 1–5, 2000.
91. XVI Figo World Congress. Washington, DC. September 5, 2000.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

92. Fifth General Scientific Meeting of the Taiwanese Menopause Society. Taipei, Taiwan. October 1, 2000.
93. XXIII Congreso Argentino de Ginecología y obstetricia. Rosario, Argentina. October 14–17, 2000.
94. Eighth World Congress of Gynecological Endocrinology. Florence, Italy. December 6–9, 2000.
95. International Congress on Reproductive Medicine. Antalya, Turkey. May 3–6, 2001.
96. Novo Nordisk. Satellite Symposia. Coimbra, Lisbon. May 16–17, 2001.
97. Fourth International Symposium on Women's Health and Menopause. Washington, DC. May 19–23, 2001.
98. Council of Affiliated Menopause Societies of the International Menopause Society. European CAMS Workshop on Guidelines on the Management of the Menopause. Geneva, Switzerland. June 12–14, 2001.
99. The Society of Obstetricians and Gynaecologists of Canada. St. John's, Canada. June 16, 2001.
100. Third National Gynecology & Obstetric Congress. Istanbul, Turkey. September 15, 2001.
101. Amsterdam Menopause Meeting. Amsterdam. September 22–25, 2001.
102. Novo Nordisk. HRT Advisory Meeting. Rome, Italy. December 14–16, 2001
103. Hormone Therapy. Key Opinion Leader Meeting. Mallorca. January 24–27, 2002
104. Novo Nordisk. Actiwell Launch Meeting. Istanbul. Izmir, Ankara, Turkey. February 15–17, 2002.
105. Novo Nordisk. Lahti, Helsinki, Finland. April 16–18, 2002.
106. First Scientific Meeting of the APMF. Seoul, Korea. May 26–28, 2002.
107. Second IMS Workshop: Hormone Replacement Therapy and Cancer. Pisa, Italy. June 9–12, 2002.
108. Schering Hormone Therapy Workshop Review. Frankfurt. February 26-27,2003.
109. Novo Nordisk. Expert Meeting. Madeira. February23-26 2003.
110. IMS:Third Workshop *HRT in Climacteric and Aging Brain*. Pisa. March 15-18,2003.
111. COGI Symposium. Berlin. April 25-27,2003
112. Novo Nordisk. International Symposium. Monte Carlo. April 11-13,2003.
113. Schering. Hormone Therapy Workshop:Benelux Interactive Meeting. Amsterdam. May 9-10,2003.
114. Schering.Hormone Therapy Workshop. Istanbul. May 13-14,2003.
115. FEMS Congress. Athens. May 1-4,2003.

Curriculum Vitae Morris Notelovitz, M.D., Ph.D.

116. EMAS. Bucharest. May 24-28,2003.
117. Novo Nordisk. International Symposium. Monte Carlo. September 5-7,2003.
118. International Advisory Board on Ultra. London. August 8-9,2003.
119. EMAS Workshop 4<sup>th</sup> Croatian Congress. Brijuni. Croatia. September 27,2003.
120. First Menopausal School. Szczecin, Poland. October 18-21,2003.
121. Novo Nordisk. Novofem Launch. Tel Aviv. December 12,2003.
122. IMS 4<sup>th</sup> Workshop on Climacteric Medicine. Vienna. December 1-3,2003.
123. Novo Nordisk. Advisory Board Meeting. Rome. December 4-6,2003.
124. Hormone Therapy in the Menopause. Cancun, Mexico. February 13-15,2004.
125. Second Menopause School. Ostrava,Czech Republic. October 22-24,2004.
126. Novo Nordisk. Expert Meeting. Lucerne. February 15-18,2004.
127. Novo Nordisk. International Symposium. Monte Carlo. April 2-4,2004.
128. Novo Nordisk. International Symposium. Monte Carlo. September 8-11,2004.
129. IMS 5<sup>th</sup> Workshop:Osteoporosis. Pisa. November 13-16.2004.
130. 12<sup>th</sup> World Congress on Human Reproduction. Venice. March 10-13,2005.
131. Lithuanian Menopause Society. Menopause School. Vilnius. June 2,2005.
132. Hungarian Menopause Society. Menopause School. Siofok,Hungary. June 10,2005.
133. IMS:Adult Women's Medicine Workshop. Tel Aviv. July 1-2,2005.
134. Beijing Conference of Obsterics & Gynecology. Beijing. October 8-10.2005.
135. IMS World Congress on the Menopause. Buenos Aires. October 18-20,2005.
136. IMS Board Meeting. Florence. February 2-6.2006.
137. Adult Women's Health & Medicine Workshops. Istanbul,Adana,Cappadocia Turkey.  
March 21-April 8,2006.
138. Train the Teacher, AWH&M Project. Gothenburg. May 20,2006.
139. First European Meeting on Anti-Aging. Vienna. October 20-21,2006.
140. 7th International Menopause Workshop . Budapest. February 17th-19th 2007.

**PATENTS**

Awarded

1. Composition and Methods for Treating or Preventing Neurodegeneration and Cognitive Decline and Dysfunction Associated with Alzheimer's disease, Aging, Other Dementia Related disorders and Estrogen Deficiency Related Conditions.  
US Patent 6,524,616 B1            Issues February 25, 2003
2. Methods for reducing the Risk of Breast Cancer and Improving the Health of Women.  
US Patent 6,901,278                Issued May 31, 2005
3. Method of Treating or Preventing Unscheduled Bleeding in Women on Progestogen Containing Medication.  
Notelovitz M, Coelingh Bennick HJJ, Boerrigter PJ.  
International Application No. PCT/NL 2004/000667            Issued January 2004